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The development of small molecules as therapeutic agents for targeted disease treatment 
is unable to keep up with the rapid expansion of databases cataloguing disease-causing proteins 
enabled by high throughput analysis of patient samples. As an alternative, the use of small 
interfering RNA (siRNA) provides a simple means of efficiently and specifically silencing the 
expression of these pathogenic proteins without the need for screening and development required 
of small molecules. Unfortunately, the delivery of siRNA is not trivial, and existing technology 
is characterized by either poor siRNA transfection efficiency or induction of cytotoxicity. 
Detailed work by many groups has supported the finding that low transfection efficiency is often 
attributable to endosomal entrapment. This phenomenon prevents siRNA from accessing the 
cytoplasmic compartment where it is active. Consequently, development of new siRNA vectors 
is required to safely promote endosomal escape and delivery of siRNA to the cytoplasm. This 
work focuses on the development and characterization of peptides derived from melittin, the 
membrane-lytic component of honeybee venom, for siRNA delivery. The most active melittin 
derivative, p5RHH, includes modifications to decrease cytotoxicity, increase siRNA binding, and 
ix 
 
allow triggered siRNA release in response to the acidic environment encountered during 
endocytosis. These peptides bind siRNA to form nanoparticles of 50 to 200 nm in diameter with 
a positive zeta potential (+12 mV). This low magnitude surface charge cannot stabilize the 
particles against flocculation, necessitating a subsequent coating with serum albumin to achieve 
a stable formulation. p5RHH-mediated transfection is characterized by an IC50 in the range of 
25 to 100 nM without cytotoxicity at all tested doses. Furthermore, the activity of p5RHH is 
attributed to efficient endocytosis via macropinocytosis with nanoparticle disassembly in the 
endosome. Particle disassembly releases both siRNA and peptide, allowing p5RHH to disrupt the 
endosomal membrane and siRNA to access the cytoplasmic compartment. To demonstrate broad 
transfection potential, p5RHH-mediated transfection has been utilized to treat in vitro models of 
cancer, angiogenesis, and atherosclerosis. Furthermore, in vivo studies demonstrate the ability of 
p5RHH/siRNA nanoparticles to deposit in tumors with little accumulation in clearance organs 
such as the liver and spleen. Instead, these studies reveal siRNA clearance via the kidney. Our 
results indicate that melittin can be modified for efficient and safe nanoparticle-mediated siRNA 
transfection, potentially enabling the clinical use of siRNA. Moreover, our analysis of p5RHH’s 
mechanism of action provides a framework to guide the future development of peptide vectors 
for siRNA transfection.
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Chapter 1 
Introduction 
 
1.1 Nanomedicine 
The National Institutes of Health define nanomedicine as “an offshoot of 
nanotechnology, [referring] to highly specific medical interventions at the molecular scale for 
curing disease or repairing damaged tissues,…”1 This definition highlights the potential of 
improved medical treatments by leveraging the unique properties of nanoscale materials. For 
example, nanoparticles with diameters less than 1,000 nanometers are expected to provide 
improvements over existing medical technology by enhancing the performance of known drugs 
and enabling the use of previously bio-incompatible therapeutics.2-6 These highly desirable 
characteristics have made nanoparticle development a focus of research since polyacrylamide 
nanoparticles were first published in the 1970s.7  
Early work in the field of nanoparticle-mediated drug delivery has established that the 
ability of nanoparticles to improve drug performance stem from their inherent ability to alter a 
drug’s interaction with the body. Notably, nanoparticles improve the pharmacokinetics and 
biodistribution of the drugs they carry.8, 9 On the most basic level, nanoparticles enable the use of 
potentially beneficial drugs that have been discarded due to a lack of biocompatibility. For 
instance, insoluble drugs that are unable to be delivered via oral or parenteral means can be 
packaged inside of a carrier nanoparticle for delivery into the body.10 
Perhaps of even greater utility is the ability of nanoparticles to enable “targeted delivery,” 
a drug delivery paradigm which is characterized by delivery of a therapeutic to a specific 
location within the body.11 Examples include delivery of antibiotics to infected tissues, 
chemotherapy to tumors, or even anti-inflammatory agents to sites of inflammation.2, 5, 12, 13 By 
taking advantage of this property, drugs that have a poor therapeutic index due to systemic side-
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effects become clinically relevant because they no longer enter non-target tissues. For instance, 
liposomal formulations of the chemotherapeutic, doxorubicin, not only prevent the cardio-
toxicity associated with free doxorubicin by decreasing deposition in cardiac tissue but also 
improve the ability of doxorubicin to exert anti-tumoral effects.14 This example highlights the 
ability of nanoparticles to improve drug delivery to diseased tissue while minimizing the 
systemic dose for increased therapeutic benefit. Based on these principles, over 40 nanoparticle 
formulations have been approved for clinical use to date, indicating that nanoparticle-based drug 
delivery has already begun to impact the practice of medicine.15 
 
1.2 RNA Interference by siRNA 
RNA interference (RNAi) refers to an evolutionarily conserved mechanism for post-
transcriptional control of protein expression in which short double-stranded RNA (dsRNA) 
target specific messenger RNA (mRNA) for degradation, thus preventing protein translation.16 
This evolutionarily conserved mechanism is thought to protect against viral infection in yeast 
and regulate cellular processes in higher eukaryotes.17 In the context of cellular regulation, the 
RNAi machinery is designed to utilize short, 21 to 25 nucleotide, double-stranded micro RNA 
(miRNA). miRNA are originally encoded in a long primary RNA which is processed in the 
nucleus by Drosha to produce a hairpin-structured primary miRNA (pri-miRNA). pri-miRNA are 
then exported from the nucleus for final processing by the RNase III endonuclease DICER 
before loading onto the RNA-induced silencing complex (RISC).18 Loaded miRNA subsequently 
target the RISC to mRNA through complementary base pairing (Figure 1.1).19, 20 Notably, 
mRNA targeting via miRNA only requires partial base pairing by the miRNA sequence. The 
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resulting RNAi is traditionally thought to be a result of translational repression, but in some 
cases, miRNA can induce mRNA cleavage by the RISC’s argonaute-2 subunit.20, 21 
Although RNAi in eukaryotes is natively initiated by the production of endogenous 
miRNA, Tuschl et al. have demonstrated that RNAi can be artificially induced by the delivery of 
exogenous small interfering RNA (siRNA) into the cytoplasm of mammalian cells.22 siRNA are 
short 21 to 23 base pair duplex RNA oligonucleotides with 5’-phosphorylated ends and two-
nucleotide 3’ overhangs similar to the structure of endogenous miRNA. The “antisense” strand 
shares sequence complementarity to a target mRNA, while the “sense” strand serves as a 
bystander. When delivered into the cytoplasm of a cell, siRNA can co-opt the native RNAi 
machinery and induce assembly of the RISC. The RISC unwinds siRNA, binds the antisense 
strand, and cleaves the sense strand.23 This allows the antisense strand to base pair with target  
 
 
Figure 1.1 RNAi Pathways 
Endogenous RNAi is induced by miRNA, which results in translational repression. Alternatively, 
exogenous siRNA can induce RNAi by mediating mRNA degradation. 
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mRNA. In contrast to miRNA-based mRNA silencing, siRNA are designed to base pair 
completely with the desired mRNA and function solely by inducing mRNA cleavage (Figure 
1.1).24 This catalytic mechanism allows one siRNA to induce degradation of multiple mRNAs 
and leads to efficient, prolonged downregulation of protein expression for 5 to 7 days. Indeed, 
RNAi induced by siRNA is only limited by its dilution through cell division.25 
The ability of exogenously delivered siRNA to silence protein expression has limitless 
potential for the realization of personalized medicine. By silencing the expression of any 
combination of proteins involved in disease pathogenesis on an individual basis, a patient’s 
particular disease processes can be specifically inhibited with few off-target toxicities. Notably, 
siRNAs can be developed against these targets without the lengthy lead identification and 
optimization required of small molecule drug development. Given the advantages of siRNA as a 
potential therapeutic, there has been a dramatic push to translate siRNA from a research tool to 
clinical applications.26 Recently, clinical trials have been initiated for the use of naked siRNA in 
ocular, renal, and hepatic diseases.27 
1.2.1 Barriers to the Therapeutic Use of siRNA 
There are several significant challenges that need to be resolved before siRNA can be 
widely used as a therapeutic. On a cellular level, the mechanism of siRNA action dictates that 
siRNA must be delivered to the cytoplasm. This requirement represents the primary hurdle 
limiting siRNA’s utility as both a basic science research tool and as a clinical therapeutic. 
Unfortunately, siRNA are large (~21 kDa) and highly charged, which hinders its direct 
translocation across the hydrophobic core of the cellular membrane.28 Moreover, the barrier 
provided by impermeable membrane bilayers not only applies to direct translocation from the 
extracellular milieu into the cytoplasm but also cytoplasmic access of siRNA enclosed in 
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endocytic vesicles.29 Entrapment of siRNA in endocytic compartments prevents siRNA from 
reaching the cytoplasm and accelerates siRNA degradation by the harsh acidic environment 
encountered during endosomal/lysosomal trafficking.30 
 siRNA delivery in an in vivo setting is further complicated by rapid clearance. First, an 
abundance of serum RNases causes siRNA cleavage with a half-life of less than 20 minutes.31, 32 
Moreover, the size of siRNA (~7.5 nm) allows naked siRNA to be cleared quickly through the 
kidney into the urine, as the glomerular basement membrane has a pore size of 10 nm. Detailed 
studies have shown that systemically injected siRNA accumulates in the kidney and is excreted 
into the urine within one hour.33 The lability of siRNA in serum and rapid clearance of siRNA by 
the kidney lead to a short circulation half-life, preventing siRNA accumulation in diseased 
tissue.34  
Use of siRNA is further limited by the innate immune system. Specifically, pattern 
recognition receptors found in both immune and non-immune cells allow highly sensitive 
detection of dsRNA, a telltale sign of viral infection.35 These receptors include Toll-like 
Receptor (TLR) 3 on the cell surface, TLRs 7 and 8 in the endosomal/lysosomal pathway, and 
Protein Kinase R (PKR) and Rig-I in the cytoplasm.36 Spatial separation of these receptors 
allows detection of dsRNA in all compartments for a robust antiviral response, leading to 
decreased translation of viral proteins and expression of inflammatory cytokines. Fortunately, 
detailed studies regarding the activation of these receptors reveal that synthetic dsRNAs less than 
23 base pairs with two-nucleotide 3’ overhangs and minimal GA/GU regions are able to 
minimize the induction of innate immune responses.35, 37 
Despite the myriad barriers preventing the utilization of siRNA as a therapeutic, siRNA-
based therapy is moving towards clinical application as solutions to bypass these barriers are 
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developed. For example, optimization of siRNA chemistry using phosphorothioate backbones 
and 2’O-methyl ribose sugars has improved the resistance of siRNA to serum proteins.38-40 While 
these solutions resolve some of the problems associated with siRNA delivery, the most 
fundamental difficulties remain unsolved. Without a mechanism to promote siRNA entry into the 
cytoplasm, the clinical utility of naked siRNA will be limited.41, 42 
 
1.3 Nanoparticles for siRNA Delivery 
The application of nanoparticle technology to siRNA delivery solves many of the 
challenges associated with in vivo siRNA delivery. Most importantly, nanoparticles can be used 
to package siRNA to improve the pharmacokinetic profile of siRNA. By incorporating siRNA 
into a carrier nanoparticle, siRNA are inaccessible to serum endonucleases and thus, protected 
from degradation. Moreover, nanoparticles with a diameter larger than 10 nm will exhibit 
minimal glomerular filtration and decreased kidney clearance.43 Nanoparticles can also impart 
additional benefits on siRNA-based therapy by enabling targeted delivery. Given the potential 
for erroneous gene silencing in non-diseased tissue, targeted delivery is critical for increased 
patient safety when utilizing siRNA therapies designed to target endogenous genes.44-46 When 
considering the challenges associated with systemic delivery of naked siRNA, it appears that the 
application of nanoparticle technology is perfectly suited to increase siRNA’s circulation half-
life and bioavailability. 
On a cellular level, nanoparticles also prove advantageous for increasing siRNA uptake. 
By masking the negative charge of the siRNA backbone, nanoparticles can improve association 
with the cell membrane via electrostatic association with negatively charged proteoglycans or by 
binding cell surface receptors. Both mechanisms can lead to increased endocytosis and cellular 
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uptake. With these properties, nanoparticles can be considered to be siRNA-carrying Trojan 
horses which protect siRNA and induce cellular uptake while avoiding TLR-mediated activation 
of the innate immune system.47 
1.3.1 Challenges Facing Nanoparticle-Mediated siRNA Delivery: Design Criteria 
Despite the initial success of some nanoparticle-siRNA formulations, widespread use of 
nanoparticle-siRNA technology is still hindered by limitations such as stimulation of innate 
immunity, vascular constraint, clearance via the reticulo-endothelial system (RES), and 
endosomal entrapment.48 When injected into the blood stream, siRNA-carrying nanoparticles 
encounter plasma proteins including components of the complement cascade. Complement 
activation can cause degradation of liposomal carriers or stimulate a systemic inflammatory 
response.9, 49 Intravenous administration of nanoparticles also contributes to poor nanoparticle 
biodistribution. Specifically, endothelial tight junctions limit the ability of nanoparticles to 
extravasate, thus preventing therapeutics from reaching their target site and promoting clearance 
by macrophages in the liver and spleen.50 Even when nanoparticles are able to extravasate and 
enter the targeted cell, effective siRNA delivery can be limited by inappropriate subcellular 
localization. Nanoparticle entry via endocytosis often constrains nanoparticles to the endosomal 
pathway, ultimately resulting in siRNA degradation in the lysosomes.51  
These challenges have prevented nanoparticles from achieving the therapeutic benefits 
often espoused by the field of nanomedicine. To overcome these barriers, the ideal siRNA 
delivery vector should meet the following criteria: 1) package siRNA to prevent degradation by 
serum endonucleases and minimize glomerular filtration, 2) provide sufficient circulation half-
life to allow delivery to the target organ while avoiding RES uptake, 3) avoid opsonization and 
stimulation of an immune response, 4) induce endocytosis via cell surface receptor binding or 
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nonspecific electrostatic association with the cell membrane, 5) promote endosomal escape to 
deliver siRNA to the cytoplasm, and 6) exhibit minimal cytotoxicity. 
As nanoparticles have matured, difficulties associated with toxicity, immune stimulation, 
and RES-mediated clearance have been addressed through improved nanomaterials. Notably, 
criteria two through four apply to in vivo usage, and while they are not trivial, have been solved 
by a combination of pegylation and active targeting.8, 52 Pegylation of nanoparticles decreases the 
interaction of serum proteins with nanoparticle surfaces via steric hindrance provided by 
hydrophilic polyethylene glycol (PEG) polymers. By preventing opsonization, nanoparticles are 
no longer rapidly cleared by scavenger receptor-carrying macrophages in the RES. For instance, 
cyclodextrin nanoparticles rely on pegylation to decrease opsonization and therefore limit RES 
clearance allowing long circulation half-lives.53, 54 These nanoparticles can then slowly penetrate 
tumors to deliver therapeutic siRNA to tumor cells via active targeting to the transferrin receptor. 
Unfortunately, existing solutions have had difficulties fulfilling criteria five and six, which are 
specific to the siRNA delivery vector itself. Existing siRNA delivery technology has traditionally 
exhibited efficient endosomal escape with high cytotoxicity or poor endosomal escape with low 
cytotoxicity.55, 56 Consequently, there is a need for new siRNA delivery technology to enable 
endosomal escape with minimal cytotoxicity. 
 
1.4 Current siRNA Delivery Technology 
1.4.1 Viral Vectors 
Early work has utilized adenoviral vectors to deliver plasmids expressing short hairpin 
RNA (shRNA), which are converted into siRNA via the nuclease DICER. These methods can 
achieve highly efficient plasmid transfection and production of high amounts of encoded 
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shRNA.57 However, early clinical trials were halted by excessive inflammatory responses and 
induction of cancer due to genomic integration of the delivered plasmid.58-60 These difficulties 
suggest that new non-viral siRNA delivery strategies are required to fully realize the promising 
therapeutic potential of siRNA. 
1.4.2 Cationic Lipids 
Cationic lipids are the most efficient and best characterized non-viral vectors for the 
delivery of siRNA. The original class of lipid vectors was based on the cationic lipids DOTAP or 
DC-Chol mixed with a helper lipid, DOPE, to package siRNA into multi-lamellar lipoplexes.61 
Importantly, cationic lipids are also able to induce disruption of endosomal membranes 
(endosomolysis) by altering lipid bilayers to favor non-bilayer structures.62 Unfortunately, the 
efficiency with which cationic lipids disrupt membrane bilayers also leads to considerable 
cytotoxicity.63 A new generation of synthetic lipids (lipidoids) delocalizes cationic charge over a 
large headgroup and exhibits both drastically reduced cytotoxicity and increased siRNA 
transfection efficiency.64, 65 Unfortunately, in vivo results have not been as successful as those 
from in vitro studies owing to heterogeneity in lipid formulations. Nonetheless, existing lipoplex 
formulations have reached Phase I clinical trials with moderate success for liver disease.66 
However, some similar lipoplex-based therapeutics have been shelved due to stimulation of 
systemic immune responses at high doses.67 Although lipoplexes are currently the primary 
vectors for in vivo applications, these findings highlight the need for further analysis of lipoplex-
mediated toxicity. 
1.4.3 Cationic Polymers 
Cationic polymers offer a high charge density with which to condense and package 
siRNA. Traditional polymer vectors include synthetic polymers such as polyethyleneimine (PEI) 
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and cyclodextrin, and natural polymers such as the polysaccharide chitosan.68 These polymers 
rely on positively charged groups to neutralize and package siRNA to allow for efficient 
endocytosis, while utilizing protonatable moieties to induce osmotic lysis of endosomes via the 
“proton sponge effect.”69 This method of endosomolysis relies on buffering of endosomal 
acidification by weak bases, allowing the ensuing accumulation of chloride counter-ions to drive 
osmotic rupture of the endosome. Despite robust endosomolysis, polymer vectors are difficult to 
optimize. The degree of optimization must be carefully controlled, as high degrees of 
polymerization provide improved siRNA compaction and transfection but also increase 
cytotoxicity via production of reactive oxygen species and destabilization of cellular 
membranes.55, 70 Despite these difficulties, polyplexes, notably cyclodextrin-based copolymers, 
have entered Phase I clinical trials for targeted cancer therapy. Unfortunately, this trial has failed 
to move forward, possibly due to low endosomal escape or nanoparticle disassembly on 
glomerular basement membranes in the kidney.71-73 
 
1.5 Cationic Peptides for siRNA Transfection 
With the observation that the Trans-Activator of Transcription (TAT) peptide from HIV 
can directly translocate across cell membranes to trans-activate the viral promoter in tissue 
culture, cell-penetrating peptides (CPPs) have become a widely utilized tool for delivery of 
therapeutics.74 Delivery of therapeutics ranging from small molecules to proteins have all been 
augmented by CPP technology.75 Based on their hypothesized ability to bypass the cellular 
membrane, CPPs were expected to enable cytoplasmic delivery of siRNA while avoiding the 
endosomal compartment. Although this has ultimately proven untrue, peptides remain a viable 
11 
 
option for siRNA delivery due to an ability to promote endocytosis and a relative lack of 
cytotoxicity. 
1.5.1 Covalent Formulations 
Initial attempts to harness peptides for siRNA transfection focused on direct chemical 
conjugation to known cell-penetrating peptides such as penetratin and transportan. These studies 
reported an IC50 of 25 nM and minimal cytotoxicity.76-78 Unfortunately, these initial studies 
were later shown to be confounded by poor purification, as excess unconjugated peptide 
augmented the transfection efficiency. Turner et al. demonstrated that after careful purification, 
siRNA conjugated to cell-penetrating peptides had minimal transfection capacity, requiring a 
concentration of 5 µM to achieve significant knockdown.79-81 They attributed the limited 
transfection capacity to endosomal entrapment based on the findings that endosomolytic agents 
such as chloroquine were able to release siRNA into the cytoplasm.82 When tested for intra-
tracheal delivery of siRNA to the lung, these purified conjugates did not exhibit any 
improvement over naked siRNA alone.83 Additional setbacks included decreased peptide-siRNA 
conjugate uptake in the presence of serum proteins.84 Nonetheless, in vitro studies investigating 
the use of peptide-oligonucleotide conjugates reinforce the safety of peptide vectors. Only 
minimal cytotoxicity has been reported with doses up to 10 µM, indicating a high degree of 
safety on a cellular level.85 
1.5.2 Non-Covalent Formulations 
Due to the limited efficacy of peptide-siRNA conjugates and the finding that excess 
peptide imbues improved transfection efficiency, peptide-based siRNA vectors have more 
commonly been utilized in non-covalent formulations (Table 1.1). Initial studies examining 
siRNA delivery via electrostatic packaging by TAT, penetratin, and transportan all produced  
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Table 1.1 Cell-Penetrating Peptides for siRNA Transfection    
Peptide Target Gene IC50 Ref 
TAT47-57 (YGRKKRRQRRR) eGFP none 81, 86 
    
Penetratin (RQIKIWFQNRRMKWKK-amide) Luciferase none 87-89 
    
Transportan (GWTLNSAGYLLGKINLKALAALAKKIL-amide) Luciferase none 87 
     TP10 (AGYLLGKINLKALAALAKKIL-amide) Luciferase none 87, 88 
    
Rn (8<n<15)    
     R9-RVG GFP 100nM 90 
     R9 VEGF none 88, 91 
     R15 VEGF 100nM 92 
    
Dermaseptin S4 Luciferase none 93 
    
MPG (Ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-amide) Luciferase >100nM 94 
     MPGΔNLS (Ac-GALFLGFLGAAGSTMGAWSQPKSKRKV-amide) 
Luciferase, GAPDH, 
Cyclin B1 30-50nM 
94, 95 
     MPG8 (Ac-βAFLGWLGAWGTMGWSPKKKRK-amide) Cyclin B1 1nM 95 
     MPGα (Ac-GALFLAFLAAALSLMGLWSQPKKKRKV-amide) Luciferase 1nM 96 
    
CADY (GLWRALWRLLRSLWRLLWRA-amide) GAPDH <1nM 97-100 
    
dsRBD Luciferase none 101 
     TAT-dsRBD GFP 400nM 102 
 
minimal siRNA-mediated knockdown despite high levels of siRNA internalization.81, 86, 87 
Further treatment with chloroquine increased siRNA-mediated knockdown, revealing that some 
of these peptides were unable to achieve sufficient endosomal escape.88 Interestingly, penetratin 
and poly-arginine peptides continued to exhibit minimal knockdown in the presence of 
chloroquine. This implies that endosomolysis alone is not sufficient for induction of RNAi, but 
efficient release from the vector is also required. These initial studies point out the requirement 
for peptide vectors to both release siRNA and promote endosomal escape in order to achieve 
maximal siRNA transfection efficiency. 
Despite these initial difficulties, the development of new peptide sequences has allowed 
siRNA delivery with non-covalent formulations. Notably, the transfection efficiency (IC50 less 
than 1 nM) of MPG and CADY is much higher than that of covalent strategies (IC50 greater than 
5 µM).103-105 Moreover, peptide vectors have demonstrated efficacy in a variety of cell types in 
tissue culture as well as successful abatement of cancer progression in mouse models.56 
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Importantly, despite increased peptide content compared to covalent formulations, non-covalent 
peptide/siRNA complexes continue to exhibit remarkable safety with minimal toxicity, even at 
high µM concentrations. Unfortunately, the limiting factor for non-covalent peptide vectors 
appears to be excessive endosomal entrapment as well as decreased transfection in the presence 
of serum proteins.98, 106 
1.5.3 Non-Covalent Formulations: MPG 
Initial success with peptide-mediated siRNA delivery was achieved with MPG, a hybrid 
peptide consisting of the fusion sequence from HIV glycoprotein 41 and the nuclear localization 
sequence of the SV40 virus. MPG was originally developed for plasmid DNA transfection and 
achieves knockdown of target mRNA with an IC50 of 20 to 50 nM.94, 95, 107 Initial work indicated 
that MPG-mediated siRNA transfection via direct translocation through the cell membrane.108 
However, later studies concluded that MPG/siRNA complexes enter cells via 
macropinocytosis.109 Further sequence refinement led to a truncated form, MPG-8, as well as 
MPGα, which exhibits increased membrane-inserting properties.95, 96 Both MPG-8 and MPGα 
are characterized by sub-nanomolar IC50 when used to target luciferase. However, detailed work 
by Veldhoen et al. demonstrated that MPGα is not especially efficient and requires almost two 
orders of magnitude more siRNA "per dose" to achieve the same knockdown as Lipofectamine 
2000.96 This finding may be attributable in part to endosomal entrapment, as treatment with 
chloroquine improved transfection by nearly 20%. 
1.5.4 Non-Covalent Formulations: CADY 
CADY is the first peptide designed to specifically promote both siRNA binding and 
membrane permeability. CADY has an alpha-helical structure with an siRNA-binding face 
containing cationic residues and a membrane-binding face enriched in tryptophan residues.99 To 
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date, CADY is the most efficient peptide-based siRNA vector with an IC50 less than 0.5 nM.97 
Interestingly, CADY appears to function by direct membrane translocation as neither ATP 
depletion nor incubation at 4°C inhibits siRNA transfection.100 Nevertheless, CADY may have 
limited in vivo applications due to decreased transfection in the presence of serum proteins.98 
1.5.5 Non-Covalent Formulations: dsRBD 
Dowdy et al. further developed peptide-mediated transfection by utilizing conjugates of 
TAT and double-stranded RNA binding domains (dsRBD).101, 102 dsRBD sequences were 
modified from Protein Kinase R, a cytoplasmic protein which plays a crucial role in the detection 
of viral infection. These TAT-dsRBD conjugates were shown to transfect a variety of difficult to 
transfect cell lines such as Jurkat T-cells and endothelial cells in tissue culture with an IC50 near 
400 nM and were able to yield significant siRNA knockdown in vivo. Unfortunately, later studies 
demonstrated that, due to low binding affinities, a single dsRBD is unable to bind siRNA 
efficiently, suggesting that siRNA packaging by TAT-dsRBD is attributable to electrostatic 
TAT/siRNA interactions.110 
 
1.6 Melittin as a Basis for Endosomal Escape 
It is apparent that peptide-mediated transfection is hampered by poor efficiency due in 
part to endosomal entrapment. In this work, we employ melittin derivatives for their membrane 
inserting properties as a potential solution to enable endosomal release of siRNA. Melittin is a 26 
amino acid alpha helical peptide first purified from the European honeybee in 1958 that has a 
high affinity for lipid membranes and ultimately causes membrane lysis in its active form. 
Although the exact mechanism of membrane disruption has not fully been clarified, melittin has 
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been shown to lyse red blood cells and model membranes.111, 112 Given its lytic nature, melittin 
itself has been proposed for the treatment of cancer and bacterial infections. 
More recently, melittin has been utilized as an excipient for hepatocyte-targeted siRNA 
therapy based on its membrane-lytic properties.113 In these studies, melittin is protected by acid 
labile groups that prevent membrane insertion until exposed to the acidic endosomal 
environment.114 Activation of melittin in the hepatocyte endosome has proven to be robust and 
yields a 500-fold increase in siRNA-mediated protein knockdown in vivo. 
Unfortunately, similar studies in which siRNA and melittin are conjugated to a polymer 
backbone have not been as successful. These studies have shown that such constructs cause 
substantial cytotoxicity in tissue culture and liver necrosis with abdominal bleeding in mice.115-
117 These conflicting results highlight the difficulties of working with melittin as a therapeutic. 
Moreover, melittin has been shown to be less lytic at acidic pH, the same environment found in 
endosomes.118 Nonetheless, the apparent ability of melittin to promote endosomolysis implies 
that melittin may be a potential solution to the problem of endosomal entrapment.114 
Melittin contains a hydrophobic N-terminus and cationic C-terminus similar to the 
amphipathic sequence of previously published siRNA-transfecting peptides. In studies of 
plasmid DNA delivery, melittin was able to bind DNA but yielded poor condensation due to an 
inadequate number of basic residues.119 Polymerization of melittin improved DNA condensation 
and yielded moderate transfection. These findings suggest that for stable condensation of siRNA, 
additional basic residues must be appended to the native melittin sequence. Furthermore, our lab 
has previously demonstrated that N-terminal melittin truncations decrease cytotoxicity by two 
orders of magnitude while maintaining the peptide’s propensity to partition into lipid 
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membranes.120 By taking advantage of these modifications, melittin derivatives may provide a 
starting point for a new class of peptide vectors for siRNA transfection. 
 
 
Accordingly, we proposed to investigate the following hypotheses: 
 
Chapter 2: Given its amphipathic nature and net positive charge, melittin can be modified to 
perform as an siRNA delivery vehicle with minimal cytotoxicity. 
 
Chapter 3: Nanoparticles composed of siRNA and melittin derivatives function by disassembling 
in the endosome, releasing free peptide to trigger endosomal escape. 
 
Chapter 4: Melittin derivatives can transfect siRNA into a variety of cell types for the treatment 
of clinically relevant disease processes. 
17 
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Chapter 2 
Novel Melittin-Derived Peptides for siRNA Transfection 
 
2.1 Abstract 
Traditional transfection agents such as cationic lipids and polymers have high siRNA 
transfection efficiency but cause extensive cytotoxicity. Alternatively, CPP-based transfection 
agents exhibit improved cytotoxicity profiles but do not have the efficiency of existing lipidic 
agents due to endosomal entrapment. As a consequence, we propose an alternative strategy for 
efficient peptide-mediated siRNA transfection by starting with melittin, a known membrane-lytic 
peptide. Through the incorporation of modifications designed to decrease cytotoxicity and 
improve siRNA binding, we have generated a panel of melittin derivatives with the ability to 
transfect siRNA. The most active variant, p5RHH, can complex siRNA to form nanoparticles 50 
to 200 nm in diameter at peptide to siRNA ratios of 100 to 1. These nanoparticles are stabilized 
by weak electrostatic repulsion (zeta potential +12 mV) with loss of activity over time due to 
flocculation. Despite particle instability, p5RHH does not induce cytotoxicity and exhibits high 
efficiency with greater than 50% GFP knockdown at 50 nM, as determined by RT-PCR. 
Moreover, kinetically stabilized formulations can be achieved by coating the particles with 
albumin, preventing flocculation for over 72 hours. These data confirm that our strategy for 
development of siRNA-transfecting peptides can provide an alternative avenue to safe and 
effective siRNA transfection. 
 
NOTE: Portions of this chapter are adapted from previously published work. 
Hou, K.K.; Pan, H.; Lanza, G.M.; Wickline, S.A., Melittin derived peptides for nanoparticle 
based siRNA transfection. Biomaterials 2013, 34 (12), 3110-3119.   
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2.2 Introduction 
RNAi induced by siRNA has been proposed as a highly effective therapy for myriad 
diseases including cancer and atherosclerosis.1, 2 However, despite nearly two decades of intense 
research since ground breaking work by Tuschl et al. revealed the potential for siRNA in 
mammalian cells, siRNA therapeutics have demonstrated limited success in translation to clinical 
applications.3, 4 The major barriers preventing successful siRNA-based therapeutics comprise 
poor cellular uptake and instability of free siRNA in serum. Its large molecular weight (~21 kDa) 
and high charge density prevent siRNA from passing through the cellular membrane to reach the 
cytoplasmic compartment where siRNA is active, thus blocking successful induction of RNAi. 
These traits, combined with a serum half-life of less than 20 minutes, necessitate the packaging 
of siRNA by transfection agents.5 Such agents can protect siRNA from serum endonucleases and 
promote siRNA uptake through endocytosis. Unfortunately, endocytic pathways present a second 
barrier, as siRNA must escape the endosomal/lysosomal compartment where it is degraded by an 
increasingly acidic environment.5-9  
Despite these challenges, cationic lipids and polymers have been successfully employed 
for siRNA transfection.2, 5, 6, 10-12 Unfortunately, these classes of transfection agents often exhibit 
unacceptable cytotoxicity.13-16 The incorporation of cationic lipids into membrane bilayers within 
cells promotes siRNA release into the cytoplasm but also causes generation of reactive oxygen 
species and Ca+2 leakage, a side effect shared by high molecular weight polyetheyleneimine 
cationic polymers.15-17 Despite continued development of these siRNA vectors with the goal of 
reducing cytotoxicity, these agents have experienced difficulties when administered in vivo due 
to aggregation with serum proteins and complement activation.18-20 If the problem of systemic 
siRNA delivery is to be solved, new classes of siRNA transfection agents need to be developed. 
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CPP-based siRNA transfection agents have shown promise with respect to reducing 
cytotoxicity.21-25 Although CPP-based siRNA transfection appears nearly free of cytotoxicity, 
peptide-based transfection agents have not achieved the high efficiency of traditional lipidic 
transfection agents. Some insight has been provided by the studies of Veldhoen et al., which 
suggest that peptide-based transfection is limited by lysosomal trapping.26 Despite early work 
showing that CPPs mediate siRNA uptake in an energy independent manner,27, 28 it appears that 
nanoparticles produced by the assembly of CPP and siRNA enter cells via endocytosis and must 
escape the endosomal/lysosomal pathway to gain access to the cytosolic compartment.21, 22, 29, 30 
With this barrier in mind, existing CPP technology has achieved a new level of sophistication 
through the chemical conjugation of CPPs to membrane-active lipids or endosomolytic agents.24, 
31-33 Despite these advances, achieving transfection efficiency comparable to that of lipids has 
remained elusive. 
2.2.1 Modified Peptides for siRNA Transfection 
Modifications to cell-penetrating peptides for increased endosomal escape have centered 
on three modifications: fusion to pH-sensitive fusogenic viral peptides, conjugation to lipidic 
moieties, and modification with buffering agents to promote osmotic rupture of endosomes 
(Table 2.1).8, 34 Standard CPPs such as penetratin and TAT have been fused with portions of 
influenza proteins hemagluttin-2 (HA2), LK15, or N-E5L which mediate viral escape from the 
endosome when exposed to acidic pH.35-38 This functional pH-triggered structural change 
increases the alpha helical content of the peptide and promotes insertion into the endosomal 
membrane. In vitro, HA2 fusions have shown the ability to improve siRNA transfection when 
packaged by CPP.35 Unfortunately, this modification increases the cytotoxicity of the peptide 
with significant cell death at 1 µM.35 Furthermore, these fusion peptides are not maximally 
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efficient as treatment with chloroquine improves siRNA transfection. This indicates that 
endosomal entrapment is a problem that is not completely addressed by these methods.36  
Additional attempts to increase the membrane-disruptive potential of cell-penetrating 
peptides come in the form of conjugation to lipids, most commonly stearyl moieties.33, 39 
Originally developed for plasmid DNA, stearylated peptides also improve the transfection of 
small oligonucleotides such as siRNA and splice-correcting oligonucleotides.40, 41 For these 
purposes, stearyl-TP10 has proven to be more effective than stearyl-penetratin, stearyl-TAT, or 
stearyl-R8. Studies utilizing un-stearylated peptides suggest that differences in these stearylated 
variants may be due to the ability of the peptide to release siRNA.42, 43 Moreover, in the case of 
stearyl-TP10, authors noted that improved transfection may not be due to improved endosomal 
escape but may actually be attributable to improved particle stability and increased siRNA 
uptake.42 In fact, treatment with chloroquine doubled siRNA-mediated knockdown, again 
revealing poor endosomal release. 
The importance of endosomal pH buffering as a release mechanism has led researchers to 
take advantage of histidine residues as a potential trigger for endosomal escape.44 Histidine 
residues are unique for their ability to be protonated at acidic pH (pKa ~6) while remaining 
uncharged at neutral pH. By incorporating high percentages of protonatable histidine residues, 
poly-arginine and TAT have been modified to increase their ability to deliver nucleotides to the 
cytoplasm. For instance, the addition of ten histidine residues to TAT improves plasmid DNA 
transfection by 7000 fold over TAT itself.45 
Other researchers have combined these strategies to improve peptide-mediated 
endosomal escape. By taking advantage of stearylation and conjugation to the proton-buffering 
agent chloroquine, Andaloussi et al. have created Pepfect6, which has an IC50 less than 10 nM 
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in a variety of cell types.46-48 Despite high efficiency transfection of hepatocytes in vivo, further 
analysis reveals that Pepfect6/siRNA particles demonstrate an increase in size and a mild 
decrease in transfection in the presence of serum proteins.46 Despite these difficulties, the 
incorporation of these modifications is indicative of the need for supplementary endosomolytic 
agents to improve the endosomal-escape properties of existing CPPs. 
In this chapter, we propose an alternative strategy for efficient peptide-based siRNA 
transfection based on modification of the cytolytic peptide, melittin, which is the pore forming 
component of honeybee venom. Melittin’s ability to form pores in membrane bilayers suggests 
that it can serve as a foundation for the development of simple peptides, which can improve 
 
Table 2.1 Modified Peptide Vectors   
Modified Peptides Benefit Ref 
TAT   
    Stearylation Improved siRNA uptake/Endosomal escape 40 
    HA2 conjugation pH-triggered endosomal escape 49 
    LK15 conjugation Endosomal escape 50 
    Histidine10 conjugation pH-triggered endosomal escape 45 
    
Penetratin   
    HA2 conjugation pH-triggered endosomal escape 51 
    Stearylation pH-triggered endosomal escape 42 
    
Poly-Arginine    
    Stearylation Endosomal escape 42, 52 
    Myristoylation Brain targeted delivery 53 
    Cholesterol conjugation Increased particle stability/Endosomal escape 54 
    Stearylation and insertion of histidine Endosomal escape 55 
    
Poly-Lysine    
   Insertion of histidine Endosomal escape 44, 56, 57 
    
TP10   
    EB1 Endosomal Escape 58 
    Stearylation Improved siRNA uptake/Endosomal escape 42 
    Stearylation and chloroquine conjugation pH-triggered endosomal escape 46, 48, 59 
    
MPG8   
    Cholesterol conjugation Improved particle stability/Endosomal Escape 60 
    
Calcitonin-derived peptides   
    Myristoylation Improved siRNA uptake/Endosomal Escape 36 
    HA2 conjugation Improved siRNA uptake/pH-triggered endosomal escape 36 
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endosomal escape, thereby setting the stage for efficient siRNA-mediated RNAi. Previous work 
in our lab has shown that melittin can be modified to attenuate its cytotoxicity while maintaining 
its propensity for interacting with membrane bilayers.61, 62 By incorporating these changes along 
with modifications to enhance peptide/siRNA interactions, we hypothesize that melittin-derived 
peptides can safely transfect siRNA by improving siRNA delivery to the cytoplasmic 
compartment. 
 
2.3 Materials and Methods 
2.3.1 Preparation of Peptide/siRNA Nanoassemblies and Analysis 
Melittin derivatives were synthesized by Genscript (Piscataway, NJ), dissolved at 10 mM 
in RNase/DNase free water (Sigma, St. Louis, MO) and stored in 4 µL aliquots at -80˚C before 
use. p5RHH/siRNA transfection complexes were prepared by diluting p5RHH 1 to 200 in 
phosphate buffered saline (PBS, Sigma), vortexing for 30 seconds followed by addition of the 
appropriate amount of siRNA (stock concentration of 10 µM in 1x siRNA buffer (Thermo 
Scientific, Waltham, MA)) and incubating for 40 minutes at 37˚C with shaking on an Eppendorf 
Thermomixer R. Resulting nanoparticles were analyzed for siRNA incorporation by resolution 
on a 12% polyacrylamide gel followed by ethidium bromide staining. Dynamic light scattering 
(DLS) and zeta potential measurements were performed on a Zeta Plus particle sizer 
(Brookhaven Instruments, Newton, MA). Serum stability analysis was performed by incubating 
freshly formed peptide/siRNA nanoparticles in 500 µg/mL human serum albumin (HSA, Sigma) 
overnight followed by DLS and zeta potential measurements. Wet-mode atomic force 
microscopy was performed by ARC Technologies (White Bear Lake, MN). 
2.3.2 Analysis of p5RHH Disulfide Bond Formation 
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 p5RHH was diluted to 5 mM in 20% DMSO and allowed to oxidize for 24 to 72 hours at 
4°C. Disulfide bond formation was quantified using Ellman’s Reagent (ER) (20 mM stock in 
buffer 8 (0.1 M NaH2PO4, 0.2 mM EDTA, pH 8)). Briefly, p5RHH was diluted 1 to 500 into ER 
working solution (40 µM) and allowed to incubate at 37°C for 25 minutes. After the incubation, 
UV absorbance was measured at 412 nm. A standard curve of freshly prepared L-cysteine was 
used to allow quantification of thiol oxidation. 
2.3.3 Cell Culture 
B16-F10 (ATCC, Manassas, VA) cell lines were maintained under standard cell culture 
conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Gibco). B16-F10 cells stably expressing GFP were 
produced as follows: B16-F10 were transfected (Lipofectamine 2000, Invitrogen) with a fusion 
of eGFP (pEGFP-N1, Clontech) and the PEST sequence from mouse ornithine decarboxylase 
(S421-V461) in pEF6V5HisTOPO (Invitrogen); cells were selected for four rounds with cell 
sorting by flow cytometry without antibiotic selection; an aliquot of cells was maintained in 
continuous culture for a month without a noticeable change in eGFP expression.  
2.3.4 siRNA Transfection 
Cells were plated in 6-well plates 12 hours before transfection and cultured under 
standard cell culture conditions. p5RHH/siRNA nanoparticles were prepared and incubated with 
cells for 4 hours in a final volume of 1 mL Optimem I (Gibco) or appropriate media 
supplemented with 10% FBS. Transfections were scaled accordingly for cells plated in 12-well 
plates based on cell culture surface area. After transfection, cells were washed twice with PBS 
and incubated with standard cell culture medium for another 24 to 72 hours before analysis. 
Lipofectamine 2000 was used in accordance with the manufacturer’s protocol. Briefly, 
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Lipofectamine 2000 was diluted in Optimem I to a final concentration of 8.4 µg/mL and 
incubated at room temperature for 15 minutes. siRNA was then added to the diluted lipid and 
incubated for another 40 minutes before dilution to 1 mL total volume with Optimem I for 
transfection. eGFP siRNA (Sense: 5’-GACGUAAACGGCCACAAGUUC-3’) was purchased 
from Sigma. Scrambled siRNA was purchased from Qiagen (Valencia, CA). 
2.3.5 Plasmid DNA Transfection 
 HEK293 cells were plated in 6-well plates at a density of 150,000 cells/well. 3 µg of 
plasmid DNA coding for GFP was mixed with p5RHH at a charge ratio of 12 to 1 for 40 minutes 
at 37°C. Cells were transfected overnight, and GFP expression was observed via fluorescence 
microscopy. Lipofectamine 2000 was used in accordance with manufacturer recommendations. 
2.3.6 Western Blotting 
24 or 48 hours after transfection, 100 to 200 µL RIPA buffer (10 mM Tris–HCl (pH 7.5), 
150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
1 mM EDTA, 5% glycerol) with 1 mM PMSF and Complete Protease Inhibitor Cocktail (Roche) 
was added to each well of a 6-well plate and incubated on ice for 1 hour. Cell lysates were then 
centrifuged at 4˚C for 5 minutes and supernatants stored at -20˚C. Lysates were resolved on 
Nupage Bis-Tris gels (Life Technologies) and transferred to 0.22 µm nitrocellulose before 
blocking in 5% bovine serum albumin (Sigma) in TBS-T. Primary antibodies used included 
rabbit anti-GFP (1:1,000, Novus Biologicals, Littleton, CO) and mouse anti-β-actin (1:1,000, 
Sigma), Secondary antibodies used included anti-rabbit HRP (1:5,000, Santa Cruz 
Biotechnology) and anti-mouse HRP (1:5,000, Santa Cruz Biotechnology). Blots were developed 
using ECL Western Blotting Substrate (Pierce, Rockford, IL).  
2.3.7 Real-Time PCR 
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24 hours post-transfection, cDNA was produced using the FastLane Cell cDNA kit 
(Qiagen). cDNA was stored at -20˚C until use. mRNA levels were quantified on an Applied 
Biosystems 7300 System (Applied Biosystems, Carlsbad, CA) using iTaq SYBR green with 
ROX (Bio-Rad, Hercules, CA). Quantitect Primer Assay (Qiagen) provided gene-specific 
primers for each gene. Genes of interest were normalized to species-appropriate β-actin. Results 
are reported as the average “fold change” relative to untreated controls for three separate 
experiments. 
2.3.8 Flow Cytometry 
24 hours after B16-GFP cells were transfected with p5RHH/siRNA nanoparticles 
containing GFP-specific or scrambled siRNA, cells were trypsinized and resuspended in FACS 
buffer (HBSS with 0.2% FBS and 0.5 mM EDTA) for analysis of GFP fluorescence. 
2.3.9 Cell Viability Assay 
Cell viability was determined 72 hours post-transfection using Alamar Blue (Life 
Technologies). Briefly, Alamar Blue was diluted 1 to 10 into phenol red-free media and 
incubated with cells for 2 to 4 hours. Fluorescence was measured on a fluorescent plate reader 
with excitation at 570 nm and emission at 585 nm (Varian Cary Eclipse, Agilent Technologies, 
Santa Clara, CA). 
 
2.4 Results 
2.4.1 Screening for siRNA Knockdown 
Knockdown of GFP in B16 cells stably expressing GFP-PEST allowed quick screening 
for effective siRNA knockdown of GFP expression as the addition of the PEST sequence leads 
to ubiquitination and shortens GFP half-life from 26 to 10 hours.63 Melittin derivatives were 
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chosen based on modifications designed to decrease cytotoxicity as well as improve interactions 
with oligonucleotides. These peptides were screened for their ability to deliver GFP siRNA to 
initiate GFP knockdown in B16-GFP cells (Table 2.2). Three peptide/siRNA ratios 
corresponding to charge ratios of 6 to 1, 12 to 1, and 24 to 1 were chosen to allow sufficient 
positive charge to neutralize and condense siRNA. While melittin itself was too toxic in this 
concentration range, four melittin derivatives exhibited GFP knockdown as demonstrated in 
Figure 2.1. A quick comparison of the peptide sequences exhibiting knockdown reveals that all 
functional sequences contain histidine residues, pointing to a potential role for these residues in 
siRNA transfection by melittin derivatives. Of these four, p5RHH and p5RWRH exhibited the 
best performance. Ultimately, p5RHH was chosen for further characterization and optimization 
of formulation based on its ability to transfect siRNA when formulated in multiple buffers 
including phosphate buffered saline (PBS), Hank’s Balanced Salt Solution (HBSS) and Optimem 
I (unpublished observations). 
2.4.2 Optimization of Nanoparticle Formulation 
Based on the overall net positive charge of the melittin derivative, p5RHH, we 
anticipated that p5RHH would interact electrostatically with negatively charged siRNA. 
Therefore, formulation of p5RHH/siRNA nanoparticles was optimized based on p5RHH to 
siRNA ratio as well as the incubation duration allowed for nanoparticle formation. We monitored 
these interactions at varying peptide to siRNA ratios by gel retardation assays, in which only 
unbound siRNA could migrate into the polyacrylamide gel under the presence of an electric 
field. In these assays, a set amount of siRNA was mixed with increasing amounts of p5RHH in 
PBS for 40 minutes before loading on a gel (Figure 2.2a). From these gels, it is apparent that a 
peptide to siRNA ratio of at least 50 to 1 is required to stably compact siRNA. 
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Figure 2.1 Screening of Melittin Derivatives  
Four melittin derivatives generate GFP knockdown: (a) p5RWRH, (b) p5RH, (c) p5RHH, and (d) p5RH-
LL. (–) B16-GFP control, (–) GFP siRNA-treated cells, (–) Fraction exhibiting knockdown. 
Table 2.2 Sequences Screened for siRNA Transfection 
Sequence Modification  Hypothesis  
Particle 
composition 
(peptide:siRNA)  
Charge ratio 
(+/-)  
Able to 
transfect?  
Melittin 
GIGAVLKVLTTGLPALISWIKRKRQQ  --  --  
62:1 6:1 No 
124:1 12:1 Toxic 
248:1 24:1 Toxic 
      
Peptide 5C 
VLTTGLPALISWIKRKRQQC  
N -Terminal 
Truncation  Increased Safety  
62:1 6:1 - 
124:1 12:1 No 
248:1 24:1 No 
      
Peptide 5RWR 
VLTTGLPALISWIKRKRQQRWRRRR  
N-Terminal 
Truncation  
C-Terminal Arg  
Increased siRNA 
compaction  
28:1 6:1 No 
56:1 12:1 No 
112:1 24:1 - 
      
Peptide 5RWRH  
VLTTGLPALISWIKRKRQHRWRRRR  
N-Terminal 
Truncation 
C-Terminal Arg, His  
Increased siRNA 
compaction with 
pH-triggered 
release  
28:1 6:1 Yes 
56:1 12:1 No 
112:1 24:1 No 
      
Peptide 5RH 
VLTTGLPALISWIRRRHRRC  
N-Terminal 
Truncation 
C-Terminal Arg, His 
pH-triggered 
release  
50:1 6:1 No 
100:1 12:1 Yes 
200:1 24:1 No 
      
Peptide 5RHH 
VLTTGLPALISWIRRRHRRHC  
N-Terminal 
Truncation 
C-Terminal Arg, His 
pH-triggered 
release  
50:1 6:1 Yes 
100:1 12:1 Yes 
200:1 24:1 Yes 
      
Peptide 5RH-AA 
VAKVLTTGAPALISWIRRRHRRC 
N-Terminal 
Truncation 
Leu to Ala mutation  
Increased 
endosomal 
disruption  
50:1 6:1 No 
100:1 12:1 No 
200:1 24:1 No 
      
Peptide 5RH-LL 
VLKVLTTLAPALISWIRRRHRRC 
N-Terminal 
Truncation  
Increased 
endosomal 
disruption and pore 
formation 
50:1 6:1 No 
100:1 12:1 Yes 
200:1 24:1 No 
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This finding is corroborated by flow cytometry data, which show a lack of GFP 
knockdown at p5RHH to siRNA ratios below 50 to 1 (Figure 2.2b). Indeed, transfection 
efficiency improved with increasing p5RHH content until maximal GFP knockdown at a p5RHH 
to siRNA ratio of 150 to 1. In contrast, scrambled siRNA had no effect on GFP expression levels 
under the same conditions (unpublished observations). Importantly, Alamar Blue assays revealed 
that p5RHH/siRNA nanoparticles of varying peptide to siRNA composition did not exhibit any 
cytotoxicity when delivering siRNA at 50 nM (Figure 2.2c). Although there was no sign of 
cytotoxicity associated with the peptide at ratios up to 200 to 1, we sought to minimize exposure 
to p5RHH and selected a p5RHH to siRNA ratio of 100 to 1 for the remaining experiments. 
 The interaction of p5RHH with siRNA to form particles is expected to evolve kinetically 
with increased siRNA incorporation and particle formation over time. To determine the optimal 
incubation duration to allow p5RHH/siRNA nanoparticle formation, p5RHH and siRNA were 
mixed in PBS and aliquots were taken out for transfection every ten minutes. Comparison of the 
transfection efficiency provided by each aliquot demonstrates that peak transfection efficiency 
occurred after incubation for 40 minutes with diminishing transfection thereafter (Figure 2.3a). 
2.4.3 Nanoparticle Characterization 
Nanoparticles formed at various peptide to siRNA ratios were then examined by dynamic 
light scattering and zeta potential analysis after 40-minute incubations. These data revealed that 
particle size is tied closely to the effective surface charge (Table 2.3). Particles carrying a surface 
charge near 0 mV exhibited the largest diameter, while particles with a zeta potential of greater 
magnitude had smaller diameters. The smallest particle size of 190 nm was found to be produced 
with a peptide to siRNA molar ratio of 100 to 1 or a charge ratio around 12 to 1 (+/-). It is 
important to note that increasing p5RHH to siRNA ratio to 200 to 1 (doubling the +/- ratio to 
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Figure 2.2 Optimization of Peptide to siRNA Ratio  
(a) Gel retardation assay shows that a p5RHH to siRNA ratio of 50 to 1 is required to stably complex 
siRNA. (b) FACS analysis of GFP knockdown by p5RHH/siRNA formulations of varying peptide to 
siRNA ratios show increasing knockdown at ratios from 50 to 1 to 150 to 1. (c) Cell viability assays 
confirm a lack of cytotoxicity for all peptide to siRNA ratios when transfecting 50 nM siRNA. 
Table 2.3 Nanoparticle Characterization 
Particle Composition 
(peptide/siRNA) 
Charge Ratio 
(+/-) 
Particle Size 
(nm) 
Polydispersity 
Index 
Zeta 
Potential 
(mV) 
10:1 1.2:1 300 0.110 -13±1.6 
25:1 3:1 830 0.350 -2.3±3.2 
50:1 6:1 600 0.220 3.7±0.5 
100:1 12:1 190 0.120 12.0±0.7 
200:1 24:1 320 0.110 13.1±0.7 
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24 to 1) does not change the zeta potential but results in an increased particle size. This 
phenomenon has been previously reported with other peptide transfection agents, although the 
cause has not yet been established.64  
It is important to point out that the particle size reported by DLS is the intensity-weighted 
average, and this number is calculated assuming a monomodal nanoparticle distribution. In 
reality, dynamic light scattering reveals that the 40-minute formulation actually contains a 
bimodal distribution with populations at ~100 nm and ~500 nm (Figure 2.3b). After an additional 
40 minutes, a shift in the particle populations occurs - with a decrease in particles around 100 nm 
and an increase in particles at 500 nm. Additionally, a new population at larger than 2 µm is also 
recorded (Figure 2.3c). By two hours, the majority of the particles are 500 nm and larger (Figure 
2.3d). The increase in particle size over time implies that the particles’ zeta potential is not high 
enough to stabilize them against further aggregation. 
Deep-etch electron microscopy confirms the multiple populations revealed by DLS. 
Specifically, electron microscopy shows particles ~20 nm in diameter (Figure 2.4a), ~100 nm in 
diameter (Figure 2.4b), as well as large aggregates (Figure 2.4c). Based on these images, the 
aggregation process is quite clear - the ~100 nm clusters appear to be comprised of smaller ~20 
nm particles, and the large aggregates appear to be flocs of ~100 nm clusters. Although these 
populations are different than those calculated by DLS, it is possible that the ~20 nm 
nanoparticles are not captured by DLS due to their low light scattering secondary to their small 
size. Nevertheless, it appears as though formulations consisting of only peptide and siRNA are 
not kinetically stable, and this instability may contribute to the decrease in transfection efficiency 
with increased incubation duration.  
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Figure 2.3 Temporal Evolution of p5RHH/siRNA Nanoparticles 
(a) Following transfection efficiency over time shows particle formation over 40 minutes with a slow 
decrease in transfection activity over time. (b) Number-weighted plot of particle diameter shows 
populations at 100 nm and 500 nm at 40 minutes. (c) By 80 minutes, a larger population at 5 µm appears. 
(d) At 120 minutes, 100 nm diameter particles are no longer visible. 
 
 
Figure 2.4 Deep-Etch Electron Microscopy of p5RHH/siRNA Nanoparticles  
p5RHH/siRNA formulations contain particles ~20 nm in diameter (a), clusters of particles ~100 nm in 
diameter (b), and large flocs (c). 
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Figure 2.5 Peptide Dimerization Alters Transfection Efficiency 
(a) Peptide dimerization induced by disulfide bond formation improves p5RH knockdown of GFP. (b) 
Peptide dimerization decreases p5RHH transfection efficiency. 
	  
2.4.4 p5RHH Dimerization Decreases Transfection Efficiency 
 Similar to many peptide vectors, p5RHH contains a C-terminal thiol in the form of a 
cysteine residue.27 The ability for these thiol groups to disulfide bond leading to dimer formation 
has been shown to improve the delivery of plasmid DNA due to improved DNA condensation.65 
Dimerization of p5RHH and p5RH was induced by incubation of free peptide in 20% DMSO for 
24 to 72 hours. Free thiols were then quantified by colorimetric assays using Ellman’s Reagent. 
Comparison with a standard curve of freshly dissolved L-cysteine revealed that peptides 
removed from storage at -80°C were monomeric, whereas DMSO was able to drive peptide 
dimerization. By 24 hours, 45% of the thiols were dimerized, and by 72 hours, all of the peptide 
had dimerized. When we compared these peptides against monomeric peptide we found p5RHH 
activity to diminish with increased dimerization (Figure 2.5b), but p5RH activity increased 
(Figure 2.5a). While it appears that the utility of peptide dimerization is dependent on the peptide 
itself, it is clear that the activity of p5RHH does not depend on peptide dimerization. 
2.4.5 Comparison with Lipofectamine 2000 
Dose-response analysis by flow cytometry revealed that GFP knockdown mediated by 
p5RHH is efficient with an ability to decrease GFP expression in ~70% of cells at concentrations 
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as low as 10 nM (Figure 2.6a). However, these FACS analyses reveal that p5RHH falls short of 
Lipofectamine 2000 at high concentration (200 nM) and low concentration (10 nM) (Figure 2.6), 
hinting at an as yet undetermined source of inefficiency. Additional western blotting (Figure 
2.7a,c) demonstrates that scrambled siRNA has no effect on GFP expression, while RT-PCR 
confirms that p5RHH is less efficient than Lipofectamine 2000 (Figure 2.7b,d). Specifically, 
p5RHH has an IC50 of 50 nM for GFP knockdown in B16-GFP cells compared to an IC50 of 10 
nM for Lipofectamine 2000. However, it is readily apparent that p5RHH exhibits a dramatically 
reduced cytotoxicity profile compared to Lipofectamine 2000. This melittin derivative causes 
only a minor (~3%) decrease in cell viability, even at the highest tested concentrations (Figure 
2.7c,f).  
2.4.6 p5RHH Performance in the Presence of Serum 
To ensure that our particles are stable in the presence of serum proteins, we incubated 
p5RHH/siRNA nanoparticles in 500 µg/mL human serum albumin (HSA) for 30 minutes or 
overnight. When we tested the activity of these particles, their ability to knockdown GFP 
expression was the same as fresh nanoparticles (Figure 2.8a). In comparison, nanoparticles 
incubated without HSA had no transfection ability after incubating for 12 hours. Confocal 
microscopy confirmed the ability of p5RHH to deliver oligonucleotides to the cytoplasm in the 
presence of serum proteins (Figure 2.8c,d). These data suggest that serum proteins do not 
decrease transfection by p5RHH and reveal that HSA may in fact be beneficial for particle 
stability.  
Detailed characterization of albumin’s effect on particle stability was performed using 
dynamic light scattering, wet mode atomic force microscopy, and zeta potential analysis. DLS 
revealed that the average size of nanoparticles incubated with HSA increased marginally from  
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Figure 2.6 FACS Comparison of p5RHH and Lipofectamine 2000 
Comparison of GFP knockdown by p5RHH and Lipofectamine 2000 at 10 nM (a), 50 nM (b), and 200 
nM (c) reveals that p5RHH is less effective at low and high concentrations. 
 
 
Figure 2.7 Comparison of p5RHH and Lipofectamine 2000 GFP Knockdown and Cytotoxicity 
p5RHH mediates sequence-specific knockdown of GFP with an IC50 of 50 nM as determined by western 
blotting (a) and RT-PCR (b) without cytotoxicity (c). Lipofectamine has an IC50 of less than 10 nM as 
determined by western blotting (d) and RT-PCR (e) but exhibits cytotoxicity at all concentrations (f). 
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Figure 2.8 Albumin Stabilizes p5RHH/siRNA Nanoparticles 
(a) p5RHH/siRNA nanoparticles incubated in 500 µg/mL human serum albumin maintain transfection 
efficiency overnight. (b) Wet-mode AFM reveals stabilization of p5RHH/siRNA nanoparticles with a 
mean diameter of 55 ± 18 nm. (c) Confocal microscopy 24 hours post-transfection confirms Cy3-labeled 
oligonucleotide (final concentration 100 nM) transfection in Optimem I. (d) Transfection in full media 
containing 10% fetal bovine serum does not affect delivery of Cy3-labeled oligos. (Scale bar = 10 µm) 
 
Table 2.4 Characterization of Albumin-Coated Nanoparticles 
 
Particle Size 
(nm) 
Polydispersity 
Index 
Zeta Potential 
(mV) 
p5RHH/siRNA -HSA 
(30 minutes) 190 0.120 12.0±0.7 
    
p5RHH/siRNA -HSA 
(12hours) >5,000 -- -- 
    
p5RHH/siRNA +HSA 
(30 minutes) 190 0.194 -7.0±1.0 
    
p5RHH/siRNA +HSA 
(12 hours) 220 0.191 -5.5±1.5 
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190 nm to 220 nm when compared with freshly prepared particles but remained stable for up to 
12 hours. On the other hand, plain p5RHH/siRNA nanoparticles exhibited severe aggregation 
(Table 2.4). Given the difficulty of understanding heterogeneous nanoparticle populations with 
DLS, we also utilized wet mode AFM, which confirmed that the majority of nanoparticles have a 
size of 55 ± 18nm despite the presence of some larger aggregates (Figure 2.8b). These findings 
confirm a lack of continued aggregation upon addition of serum albumin. 
To determine if albumin might be coating the nanoparticles’ surface, zeta potentials were 
measured. These studies reveal that the surface charge of nanoparticles incubated in the presence 
of albumin switched from a 12 mV to -7 mV, suggesting that nanoparticles were coated with 
negatively charged albumin (Table 2.4). When considered alongside our analysis of particle 
stability, these experiments indicate that coating the particles with albumin stabilizes them 
against continued aggregation without adverse effects on transfection efficiency. 
2.4.7 Transfection of Plasmid DNA 
 Given p5RHH’s ability to package and transfect siRNA, we also examined its ability to 
transfect plasmid DNA. We transfected HEK293 cells with 3 µg of DNA in a 6-well plate. 24 
hours post-transfection, cells were monitored for GFP expression. p5RHH was not as efficient as 
Lipofectamine 2000 with only 1 to 2% of cells exhibiting GFP expression. The increased 
transfection provided by Lipofectamine 2000 is evident by fluorescence microscopy (Figure 
2.9a,b). 
 
2.5 Discussion 
Our lab has previously explored highly efficient siRNA delivery methods based on 
cationic lipids in a novel perfluorocarbon nanoemulsion formulation.66 Despite the high  
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Figure 2.9 p5RHH Mediates Plasmid DNA Transfection into HEK293 Cells  
(a) Transfection of a GFP-containing plasmid by Lipofectamine 2000. (b) p5RHH is less efficient than 
Lipofectamine 2000 when transfecting plasmid DNA. (Scale bar = 50 µm) 
 
efficiency achieved in vitro, difficulties with cytotoxicity at high nanoparticle concentrations 
reflect the challenges that accompany traditional cationic lipid transfection agents. In the present 
work, we have modified melittin peptides to achieve high efficiency siRNA transfection based 
on the hypothesis that melittin’s membrane disrupting capacity would provide a novel means of 
overcoming endosomal entrapment, which is a key drawback to previously reported CPP-based 
siRNA transfection agents.26, 29, 35 
Indeed our experiments confirm that melittin derivatives are able to transfect siRNA into 
B16-F10 cells. Analysis of the peptide sequences reveals that addition of histidine residues 
appears to play a role in the ability of peptides to deliver siRNA. Notably, introduction of a 
histidine residue into the sequence of p5RWR enables knockdown, while adding a second 
histidine to p5RH improves its transfection capacity. While the exact function of these histidine 
residues is not clear, their importance is evident based on our peptide screening.67, 68  
Other modifications intended to improve siRNA transfection were based on increasing 
the lytic capacity of the peptide. Interestingly, acid-activatable full-length melittin has 
demonstrated effective endosomal disruption, suggesting that even cytotoxic melittin can be 
harnessed to promote siRNA entry into the cytoplasm.69, 70 Consequently, we tested two 
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additional melittin derivatives with longer N-terminal hydrophobic tails, which were expected to 
improve lysosomal disruption: p5RH-LL and p5RH-AA.71 Our results reveal that only p5RH-LL 
exhibited minimal transfection capacity. It is possible that the lack of transfection by these 
variants is attributable to poor nanoparticle stability. Specifically, nanoparticles produced by the 
incubation of these melittin derivatives with siRNA may experience accelerated aggregation due 
to increased hydrophobic interactions driven by a longer N-terminal tail. Notably, p5RH-LL 
exhibits the ability to participate in leucine zipper formation and manifests an average particle 
size of 1,061 nm after a 20-minute incubation, whereas p5RH-AA cannot partake in leucine 
zipper formation and has an average size of 455 nm, indicating that the hydrophobic N-terminus 
of the peptide may be driving particle aggregation. 
In conjunction with these data, are detailed analysis of particle size and zeta potential at 
varying p5RHH/siRNA ratios. These data reveal that particle size is dependent on zeta potential, 
causing particles of increasing surface charge to exhibit smaller average particle sizes. When 
combined with the effects of peptide hydrophobicity, a model emerges in which electrostatic 
repulsion stabilizes nanoparticles against aggregation driven by hydrophobic interactions. That 
p5RHH/siRNA nanoparticles tend to aggregate over time is not surprising in view of the low 
magnitude of the zeta potential. Traditionally, colloids are not expected to be stabilized by 
electrostatic repulsion unless the magnitude of the zeta potential is over 30 mV. Nonetheless, the 
minimal surface charge achieved (+12 mV) is strong enough to slow aggregation, allowing them 
to be stabilized by coating with serum proteins. With these methods, stable nanoparticles can be 
produced in a reproducible manner. 
The ability of p5RHH to deliver siRNA to the cytoplasm yields a quantifiable decrease in 
GFP expression at concentrations as low as 10 nM. However, p5RHH is still unable to attain the 
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level of transfection efficiency provided by Lipofectamine 2000 in B16-F10 cells. Specifically, 
Lipofectamine 2000 appears to be able to deliver higher levels of siRNA to the cytoplasm at high 
concentrations (200 nM) as well as low concentrations (10 nm). The lack of improved siRNA 
transfection by p5RHH at high concentrations may indicate saturation of the uptake pathway and 
limited entry of p5RHH/siRNA nanoparticles compared to lipid-based transfection. In addition, a 
drop-off in efficiency relative to Lipofectamine 2000 at low concentrations may be a reflection 
of the heterogeneous nanoparticle population. Because nanoparticle formulations are likely to 
contain a population of large inactive aggregates, these formulations may contain a considerable 
amount of siRNA, which is no longer available for transfection, limiting transfection at low 
concentrations. 
Nevertheless, p5RHH exhibits a substantial improvement over traditional cationic lipid-
based transfection in regards to cytotoxicity, exhibiting a minimal decrease in cell viability at all 
tested concentrations. These findings, combined with the stability of these particles in the 
presence of serum proteins, imply that p5RHH/siRNA nanoparticles would be a good test 
candidate for in vivo delivery of siRNA to intravascular targets or to diseased tissue 
characterized by endothelial barrier dysfunction.   
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Chapter 3 
p5RHH Enables pH-Triggered siRNA  
Release and Endosomal Disruption  
 
3.1 Abstract 
Characterizing the mechanism of action responsible for siRNA transfection is crucial to 
understanding the obstacles that decrease the efficiency of siRNA delivery. Based on previous 
characterization of peptide transduction domains, endosomal entrapment is thought to be the 
primary barrier diminishing the performance of peptide vectors. Melittin derivatives are 
hypothesized to overcome this barrier by safely disrupting endosomal membranes. Our studies 
reveal that p5RHH/siRNA nanoparticles are indeed endocytosed by macropinocytosis and 
trafficked to acidified endosomal compartments. A lack of transfection in the presence of 
chemical inhibitors blocking vacuolar ATPases points to endosomal acidification as a crucial 
trigger for successful siRNA delivery to the cytoplasm. In fact, endosomal pH (pH ~4 to 5) 
causes p5RHH/siRNA nanocomplex disassembly with p5RHH and siRNA release. Released 
peptide is capable of initiating hemolysis at low pH indicating the potential to disrupt endosomal 
membranes in vivo. Conversely, a non-functioning melittin derivative, p5RWR, does not respond 
to pH and cannot induce knockdown even when endosomal disruption is initiated by 
chloroquine. Taken together, these studies suggest that the ability of p5RHH to release siRNA 
and disrupt membrane bilayers at low pH is critical for siRNA transfection. Moreover, these 
findings delineate general principles regarding nanocomplex responses to endocytosis, which 
may guide the development of peptide vectors for siRNA transfection. 
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3.2 Introduction 
The use of peptides for siRNA transfection requires careful study of their mechanism of 
action, given their decreased siRNA transfection efficiency compared to lipids and polymers. By 
understanding their limitations, peptides can be better designed to function as transfection agents 
while maintaining their low level of cytotoxicity.1-9 Despite initial excitement regarding direct 
translocation of CPP-cargo conjugates through the plasma membrane,10-12 the utility of CPPs for 
delivery of therapeutic cargo has diminished after follow-up studies revealed that these findings 
were a result of fixation artifacts or an occurrence found only at high (~µM) CPP 
concentrations.13-17 In fact, uptake of CPPs has been shown to rely on energy-dependent 
endocytic mechanisms including macropinocytosis, clathrin-mediated endocytosis (CME), and 
caveolae-mediated endocytosis (CvME).18-21 Moreover, endocytosis of CPP-cargo conjugates 
can change depending on the cell type in question or the cargo conveyed by the CPP.22, 23  
Despite these uncertainties, it appears that there may be a few rules that contribute to the 
uptake of siRNA packaged with poly-basic peptides.24, 25 First, arginine-containing peptides have 
been shown to interact nonspecifically with plasma membranes through bidentate ionic 
interactions with cell surface proteoglycans such as heparan sulfate (HSPG) with decreased 
uptake after cells were treated with heparanase III.26, 27 Moreover, comparison of peptides 
enriched for lysine or arginine reveal that the stronger interaction of arginines with HSPGs 
promotes increased endocytosis of arginine-containing peptides versus lysine-containing 
peptides.28 Second, arginine-containing peptides are able to initiate actin reorganization via Rac 
activity upon binding to HSPGs on cell surfaces.21, 29 This behavior explains the finding that 
arginine-containing peptides are able to induce active endocytosis via standard endocytic routes. 
Finally, the role of active endocytosis necessitates that peptides and their cargos are likely 
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shuttled through the endosomal pathway and ultimately trapped in the endosomal compartment 
with low levels of cytoplasmic release.30-34  
The challenges associated with endosomal entrapment of therapeutic siRNA when 
delivered via peptides has been quantified by Veldhoen et al., who show that transfection 
mediated by the peptide, MPGα, requires nearly two orders of magnitude more siRNA per cell to 
achieve the same levels of knockdown as more efficient lipid-based transfection.14 Also, despite 
often being overlooked, siRNA release from the vector is another aspect of transfection that is 
crucial to successful mRNA degradation. For example, double-stranded RNA binding domains 
(dsRBD) are able to bind siRNA with high affinity and, despite high levels of cellular uptake, 
continue to lack significant protein knockdown when treated with chloroquine.35 These results 
are explained by a lack of siRNA release from dsRBD even when cytoplasmic access is provided 
by chloroquine-mediated endosomolysis. For a peptide formulation to achieve maximal mRNA 
degradation from the packaged siRNA, peptides must promote cellular entry and coordinate 
siRNA release with endosomal disruption. 
In this chapter, we demonstrate that melittin-derived peptide, p5RHH, exhibits efficient 
siRNA transfection based on its ability to coordinately trigger both nanoparticle disassembly and 
endosomal disruption upon exposure to endosomal pH. Moreover, it is clear from comparisons 
with non-functioning melittin derivatives that endosomal disruption alone does not result in 
successful induction of RNAi but requires concurrent siRNA release from the vector. The ability 
of p5RHH to coordinate these processes leads to efficient siRNA-mediated GFP silencing that is 
not improved by co-incubation with chloroquine. Our results offer general parameters that yield 
efficient siRNA delivery into the cytoplasm by peptide vectors, which may aid the development 
of non-covalent peptide vectors for improvement of siRNA therapeutics. 
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3.3 Materials and Methods 
3.3.1 Preparation of Peptide/siRNA Complexes 
Melittin derivatives were synthesized by Genscript (Piscataway, NJ), dissolved at 10 mM 
in RNase/DNase free water (Sigma, St. Louis, MO) and stored in 4 µL aliquots at -80˚C before 
use. p5RHH/siRNA transfection complexes were prepared as described in Chapter 2. 
3.3.2 Cell Culture 
B16-F10 (ATCC, Manassas, VA) cell lines were maintained under standard cell culture 
conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Gibco).  
3.3.3 Uptake Inhibition by Flow Cytometry 
B16-F10 cells in full media (DMEM with 10% FBS) were incubated with 
p5RHH/Alexa488-siRNA nanoparticles (25 nM final siRNA concentration), FITC-transferrin (5 
µg/mL, Life Technologies) or 70 kDa FITC-dextran (100 µg/mL, Sigma) in the presence or 
absence of endocytosis inhibitors or chloroquine (50 mM stock in DI H2O) for 1 hour. After 
incubation, cells were washed 3x in PBS trypsinized and resuspended in FACS buffer (HBSS 
with 0.2% FBS and 0.5 mM EDTA) for flow cytometry analysis. Endocytosis inhibitors included 
EIPA (80 µM, Sigma), filipin (100 µg/mL, Sigma), and PAO (5 µM Sigma). 
3.3.4 Confocal Microscopy 
B16-F10 cells were cultured on glass coverslips overnight before incubation with p5RHH 
nanoparticles and appropriate uptake markers for 40 minutes. HSA-coated p5RHH/Cy3-siRNA 
nanoparticles were added at a final siRNA concentration of 200 nM in the presence of either 70 
kDa FITC-dextran (10 mg/mL) or FITC-transferrin (25 µg/mL). After the incubation, cells were 
washed on ice 3x in PBS for 10 minutes and fixed in 4% PFA before mounting on glass slides 
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(Vectashield Mounting Medium with DAPI, Vector Labs, Burlingame, CA). Cells were imaged 
on a Zeiss Meta 510 (Thornwood, NY). 
3.3.5 Analysis of GFP Knockdown 
B16-GFP cells were plated at 150,000 cells/well 6-well plates and transfected 12 hours 
later at a final concentration of 25 or 50 nM siRNA in 1 mL of 10% DMEM in the presence or 
absence of 10 µM bafilomycin A1 (10 mM stock in DMSO, Sigma) or 50 µM chloroquine (50 
mM stock in DI H2O). 24 hours after transfection, cells were trypsinized and resuspended in 
FACS buffer (0.2% FBS and 0.5 mM EDTA) for flow cytometry or lysed for western blotting. 
eGFP siRNA (Sense: 5’-GACGUAAACGGCCACAAGUUC-3’) was purchased from Sigma. 
Scrambled siRNA was purchased from Qiagen (Valencia, CA). 
3.3.6 siRNA Dye Accessibility at Low pH 
Preformed p5RHH/siRNA nanoparticles were incubated in HBSS at the indicated pH for 
30 minutes in the presence of TOPRO-3 (Life Technologies) diluted 1 to 1,000. TOPRO-3 
fluorescence was measured in a 96-well plate with excitation at 642 nm and emission at 661 nm. 
Fluorescence values were then normalized to siRNA-only controls and presented as the average 
of three separate experiments. 
3.3.7 pH-Dependent Gel-Mobility Assays 
p5RHH/siRNA nanoparticles were incubated in HBSS at the indicated pH for 30 minutes 
before resolution on a 12% TBE-PAGE gel for 4 hours at 90 V. siRNA was visualized by 
staining with SYBR GOLD in 1x TBE (IBIScientific) diluted 1 to 10,000 for 15 minutes. 
3.3.8 Acridine Orange Staining for Lysosomal Disruption 
B16-F10 cells plated on coverslips were loaded with acridine orange at 1 µM for 15 
minutes and washed 3x in PBS before incubation in the presence of p5RHH/siRNA 
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nanoparticles in 10% DMEM at a final siRNA concentration of 100 nM for 12 hours. 
Alternatively, cells were exposed to chloroquine (Sigma) at 100 µM for 15 minutes prior to 
imaging. Live cells were visualized by fluorescence microscopy on an Olympus BX610 (Tokyo, 
Japan). 
3.3.9 RBC Hemolysis 
Rabbit red blood cells (RBC) were isolated from whole blood by centrifugation and 
washed in PBS 3x for before storage at 4°C. Prior to hemolysis studies, RBC were washed 3x in 
pH-appropriate HBSS and diluted 1 to 5,000. RBC in pH-specific buffer were then incubated 
with p5RHH/siRNA nanoparticles for 12 hours. RBC remnants were pelleted by centrifugation, 
and the hemoglobin content of the supernatant was measured by UV absorbance at 550 nm. 
Absorbance values were then normalized against maximum lysis by p5RHH only controls and 
presented as the average of three separate experiments. 
 
3.4 Results 
3.4.1 p5RHH/siRNA Nanoparticle Endocytosis via Macropinocytosis 
The uptake of peptide/siRNA nanoparticles has been studied in depth and appears to be 
vector dependent. For example, in contrast to the majority of published work, Crombez et al. 
conclude that CPPs promote direct membrane translocation.36 To clarify the mechanism by 
which p5RHH achieves cytoplasmic delivery of siRNA, uptake studies using Alexa488-labeled 
scrambled siRNA packaged with p5RHH were performed. Incubation of cells at 4°C results in 
near complete inhibition of p5RHH/siRNA uptake removing the possibility that p5RHH 
mediates direct membrane translocation for cytoplasmic release of siRNA (Figure 3.1). 
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To determine which endocytic pathway is responsible for p5RHH/siRNA nanoparticle 
uptake, endocytosis inhibitors were used to block specific uptake pathways. The use of 
endosomal inhibitors has been shown to be nonspecific and cell type dependent. Therefore, we 
performed uptake inhibition assays for short incubation times (1 hour) at inhibitor concentrations 
that did not affect other pathways as demonstrated by inhibition of standard endosomal markers 
transferrin (CME) and 70 kDa dextran (macropinocytosis) (Figure 3.2b-g). B16-F10 cells are 
known not to express caveolin-1, and uptake of caveolar marker Cholera Toxin B is not 
measureable in this cell type (unpublished observation). Use of these inhibitors indicate that 
macropinocytosis is the major pathway responsible for p5RHH/siRNA uptake. Macropinocytosis 
inhibitor, EIPA, dramatically reduces p5RHH/siRNA uptake whereas the CvME inhibitor, 
filipin, and the CME inhibitor, PAO, have no affect on p5RHH/siRNA uptake (Figure 3.2h-j). 
Confocal microscopy confirms the flow cytometry data, showing strong colocalization of 
p5RHH/Cy3-siRNA with 70 kDa FITC-dextran but not FITC-transferrin (Figure 3.3). Cells were 
incubated with uptake markers for only 30 minutes to avoid release of Cy3-labeled siRNA into 
the cytoplasm, which could yield cytoplasmic or nuclear fluorescence that would confound the 
analysis of these experiments. Cells exhibiting cytoplasmic release were not imaged to avoid 
these issues. Interestingly, rapid uptake and release of Cy3-labeled siRNA in less than one hour 
points to the efficient endosomal escape provided by p5RHH/siRNA nanoparticles (unpublished 
observation). 
3.4.2 Importance of Endosomal Acidification in p5RHH-Mediated Transfection 
After endocytosis, the contents of endosomes experience different fates including 
recycling to the cell surface, trafficking to specific cellular compartments, or delivery to acidic 
lysosomes for degradation. Oftentimes, endocytosed nanoparticles are subject to the latter. 
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Figure 3.1 p5RHH/siRNA Nanoparticle Uptake is Temperature Sensitive 
Two-hour uptake of p5RHH/siRNA nanoparticles is decreased by incubating cells at 4°C (c) as compared 
with 37°C (b). 
 
Figure 3.2 Uptake Inhibition Studies 
(a) Flow cytometry analysis of untreated B16-F10 control cells. (b-d) Uptake of CME-specific cargo, 
FITC-transferrin, is only inhibited by PAO, a CME inhibitor. (e-g) 70 kDa FITC-dextran, a marker of 
macropinocytosis, is only inhibited by EIPA, an inhibitor of macropinocytosis. (h-j) p5RHH/siRNA 
nanoparticle uptake is nearly completely abolished by EIPA. 
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Figure 3.3 p5RHH/siRNA Nanoparticles Co-localize with FITC-Dextran 
Confocal microscopy depicting uptake at 40 minutes (200 nM final siRNA concentration) reveals no 
colocalization of p5RHH/siRNA nanoparticles (b) with FITC-transferrin (c-d), but confirms endocytosis 
by macropinocytosis along with FITC-dextran (e-f). (Scale bar = 10 µm) 
 
Fortuitously, the change in pH along the endosome/lysosome pathway can provide a trigger for 
particle disassembly and siRNA release. The pH of endosomes and lysosomes is tightly 
controlled by acidification via membrane-bound vacuolar ATPases, reaching values as low as 
4.5.37 To determine if the low pH generated by these vacuolar ATPases is involved in siRNA 
release from the endosome, cells were incubated in the presence of Bafilomycin A1 during the 
overnight transfection to inhibit endosomal acidification. Compared with control cells 
transfected without Bafilomycin A1, Bafilomycin A1-treated cells demonstrated a near complete 
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loss of GFP knockdown as determined by flow cytometry (Figure 3.4d-f). Since Bafilomycin A1 
could be slowing p5RHH/siRNA uptake, flow cytometry examining the uptake of fluorescently 
labeled siRNA in B16-F10 cells was utilized to ensure that the concentration of Bafilomycin A1 
used in these assays did not block p5RHH/siRNA uptake (Figure 3.4a-c). These data confirm the 
importance of endosomal acidification as a trigger for the cytoplasmic release of siRNA when 
delivered to cells via p5RHH. 
3.4.3 Acidic pH Triggers Nanoparticle Disassembly 
Since endosomal acidification is crucial for the ability of p5RHH to deliver siRNA to the 
cytoplasm, p5RHH/siRNA nanoparticles were incubated at decreasing pH to ascertain how an 
 
 
Figure 3.4 Endosomal Acidification is Critical for p5RHH-Mediated Transfection 
(a-c) p5RHH/Alexa488-siRNA nanoparticle uptake after 1 hour (b) is not altered by treatment with 
Bafilomycin A1 (c). (d-f) Bafilomycin A1 drastically reduces GFP knockdown (f) compared to cells 
transfected in the absence of Bafilomycin A1 (e). 
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increasingly acidic environment affects nanoparticle integrity. Dye-binding assays using the 
nucleic acid stain TOPRO-3 reveal that siRNA becomes increasingly accessible at pH ≤ 5.5 as 
witnessed by an increase in TOPRO-3 fluorescence (Figure 3.5a). Control samples were 
analyzed to show that TOPRO-3 binding to siRNA is not affected by pH in this range 
(unpublished observation). To determine if increased dye accessibility was correlated with 
increased siRNA release, additional samples were run on a 12% polyacrylamide gel to resolve 
free siRNA (Figure 3.5b). Based on these gels, it is apparent that siRNA does not become free to 
migrate into the gel until a pH of 4.5 is achieved. Taken together, these assays reveal a strong 
pH-dependent mechanism for both particle disassembly and siRNA release with a lower pH (4.5) 
required for siRNA to be completely released than that required to initiate particle disassembly 
(pH = 5.5). 
Interestingly, p5RWR, a non-functioning melittin derivative lacking histidine residues 
among other differences, does not respond to acidic pH. In contrast to p5RHH, p5RWR does not 
demonstrate an increase in TOPRO-3 fluorescence at pH ≤ 5.5 (Figure 3.5a) and lacks siRNA 
release as measured by gel mobility (Figure 3.5b). These data suggest that the ability of 
p5RHH/siRNA nanoparticles to disassemble in response to low pH may be crucial for successful 
siRNA transfection. 
To corroborate nanoparticle disassembly, pH-dependent p5RHH release from 
p5RHH/siRNA nanoparticles was quantified using dialysis through a 10K dialysis membrane 
(Figure 3.5c). These assays reveal that approximately 40% of p5RHH remained free after 
particle assembly with a strong release of p5RHH at pH ≤ 5.5. This pH dependence matches the 
pH dependence seen for siRNA dye binding, which supports the finding that acidic pH triggers 
nanoparticle disassembly and subsequent release of both p5RHH and siRNA. 
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3.4.4 Release of Free p5RHH at Low pH Lyses Membrane-Bound Vesicles 
The importance of p5RHH release from these nanoparticles is first determined in vitro 
using RBC hemolysis assays. When incubated at decreasing pH, the ability of p5RHH/siRNA 
nanoparticles to lyse RBC becomes enhanced at pH ≤ 5.5 (Figure 3.5d). These assays were 
performed at 4°C to decrease the rate of auto-hemolysis seen at higher temperatures. RBC 
hemolysis indicates that liberated p5RHH can lyse membrane-bound structures and could 
potentially disrupt endosomal membranes in intact cells. Endosomal disruption was studied in 
tissue culture using acridine orange staining. Cells were first loaded with acridine orange, which 
fluoresces red at low pH in the endosome and green in the cytoplasm (Figure 3.5e). Endosomal 
disruption can be visualized by an increase in cytoplasmic green fluorescence as demonstrated in 
cells incubated in the presence of 100 µM chloroquine (Figure 3.5f). Similarly, cells transfected 
with p5RHH/siRNA also released acridine orange from endosomal vesicles, confirming 
endosomal disruption (Figure 3.5h). Alternatively, cells treated with p5RWR/siRNA did not 
exhibit acridine orange release, confirming that a lack of particle disassembly prevents release of 
membrane-lytic peptide and therefore endosomolysis (Figure 3.5g). 
3.4.5 Nanoparticle Disassembly Enables siRNA Delivery to the Cytoplasm 
As noted in Chapter 2, p5RHH is less efficient than traditional lipid transfection agent 
Lipofectamine 2000. When considering sources of inefficiency, p5RHH may also suffer from 
endosomal entrapment, especially at low concentrations, when the amount of endocytosed 
peptide may be too low to allow efficient endosomal escape. However, transfection of B16-GFP 
cells in the presence of chloroquine provides no benefit over transfection in the absence of 
chloroquine at doses from 10 nM to 200 nM (Only 50 nM siRNA is shown, Figure 3.6a). 
Confocal microscopy confirms cytoplasmic release of Cy3-labeled oligonucleotides when 
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Figure 3.5 pH Mediates p5RHH/siRNA Nanoparticle Disassembly and Endosomolysis 
(a) TOPRO-3 dye-binding assays reveal increased siRNA accessibility at pH ≤ 5.5 when packaged by 
p5RHH but not p5RWR. (b) Gel-mobility assays reveal siRNA release from p5RHH but not p5RWR at 
low pH. (c) p5RHH release from p5RHH/siRNA nanoparticles as measured by dialysis and UV 
absorption is increased at low pH. (d) Hemolysis by p5RHH/siRNA nanoparticles increases at pH ≤ 5.5. 
(e-h) Acridine orange release assays exhibit increased endosomolysis and cytoplasmic green fluorescence 
12 hours post-transfection when treated with 100 µM chloroquine (f) and p5RHH/siRNA nanoparticles 
(final siRNA concentration 100 nM) (h) but not p5RWR/siRNA nanoparticles (g). (Scale bar = 50 µm) 
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Figure 3.6 p5RHH Mediates Both siRNA Release and Endosomal Escape 
(a) Knockdown of GFP by p5RHH (50 nM final siRNA concentration) is not increased by co-incubation 
with 50 µM chloroquine, whereas p5RWR shows a minor improvement in knockdown. (b) p5RWR and 
p5RHH mediate similar levels of siRNA uptake. (c) Confocal microscopy 24 hours post-transfection 
reveals that Cy3-labeled oligos (at 100 nM) remain in punctate vesicles when transfected by p5RWR. (d) 
Chloroquine co-incubation yields cytoplasmic distribution of Cy3-labeled oligos when transfected by 
p5RWR. (e) p5RHH alone mediates cytoplasmic delivery of siRNA. (f) Chloroquine co-incubation does 
not alter oligo delivery by p5RHH. (Scale bar = 10 µm) 
 
transfected by p5RHH with no impact of chloroquine co-incubation (Figure 3.6e,f). Alongside in 
vitro siRNA release and acridine orange assays, these data underscore the relationship of pH-
mediated nanoparticle disassembly with effective siRNA delivery to the cytoplasm and suggest 
that inefficiencies in p5RHH-mediated transfection are not associated with endosomal 
entrapment. 
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Despite nearly equivalent uptake of siRNA (Figure 3.6b), p5RWR/siRNA nanoparticles 
are unable to initiate silencing of GFP as determined by FACS (Figure 3.6a). Analysis of 
p5RWR by confocal microscopy (Figure 3.6c) confirms that oligonucleotides packaged with 
p5RWR do not reach the cytoplasm without co-incubation in the presence of 50 µM chloroquine 
(Figure 3.6d). Interestingly, p5RWR/siRNA nanoparticles only exhibit a minimal increase in 
transfection when co-incubated with chloroquine (Figure 3.6a), despite the dramatic increase in 
cytoplasmic localization observed by confocal microscopy. This continued lack of transfection 
could be explained by poor access of siRNA to the RISC due to continued binding to p5RWR. 
This possibility is supported by a lack of particle disassembly witnessed during in vitro dye-
binding and gel-mobility assays, highlighting that nanoparticle disassembly is not only crucial 
for the release of peptide and endosomolysis but also for siRNA to initiate RISC assembly.  
 
3.5 Discussion 
Clarifying the mechanism of action underlying peptide-based siRNA transfection is 
crucial for understanding the high efficacy of siRNA transfection provided by p5RHH as well as 
identifying potential sources of inefficiency which might affect p5RHH-mediated siRNA 
delivery.14 In the past, peptides have been shown to mediate direct translocation of siRNA 
through the plasma membrane. However, recent work supports the involvement of active uptake 
of peptide/siRNA particles via endocytosis.14 While the specific pathway may be cell type and 
vector dependent, the majority of peptides appear to mediate endocytosis via macropinocytosis.30  
In a similar fashion, the current work demonstrates that p5RHH-mediated transfection 
does not rely on direct penetration of the plasma membrane as witnessed by a decrease in 
p5RHH/siRNA nanoparticle uptake at 4°C. Alternatively, the sensitivity of p5RHH/siRNA 
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nanoparticle uptake to macropinocytosis inhibitors but not clathrin-mediated uptake inhibitors 
suggests that p5RHH-mediated transfection is dependent on fluid phase macropinocytosis for 
cell entry. Detailed analysis of the uptake of cationic peptides provides insight into the 
macromolecular interactions that may contribute to this process. Specifically, arginine residues 
can form electrostatic interactions with cell surface proteoglycans, which results in close 
association with the plasma membrane.25 The robust uptake of positively charged peptides 
indicates that electrostatic association with the plasma membrane and subsequent fluid phase 
uptake is sufficient to achieve substantial peptide/siRNA uptake. Nevertheless, the ability of 
cationic peptides to interact with cell surface receptors such as CXCR4 reveals that further 
studies are required to clarify the initial interactions responsible for p5RHH/siRNA nanoparticle 
association with the plasma membrane.38 
Proper siRNA trafficking subsequent to the initial endocytic event is also vitally 
important for successful siRNA transfection. In particular, previous work has shown that siRNA 
transfection requires the coordination of both siRNA release and endosomal escape.39 Premature 
siRNA release in the endosome allows siRNA degradation by endosomal hydrolases. On the 
other hand, peptides which bind too strongly to siRNA are also hypothesized to prevent 
successful RNAi.35 Consequently, siRNA release from peptide transfection agents must be 
concurrent with endosomal escape for maximal mRNA knockdown. We have designed our 
melittin derivatives to release siRNA based on protonation of histidine residues in the siRNA 
binding portion of p5RHH. These modifications are expected to induce particle disassembly and 
release of lytic melittin derivatives to aid endosomolysis. A lack of transfection in the presence 
of Bafilomycin A1 demonstrates the importance of endosomal acidification in the transfection of 
siRNA by p5RHH.  
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Indeed, dye-accessibility assays and siRNA release as monitored by gel retardation 
assays reveal that acidification triggers particle unpackaging with release of membrane-active 
peptides. The release of p5RHH was quantified and displays the same pH dependence with 
increased peptide release at pH ≤ 5.5. Importantly, this pH dependence was also seen when 
studying RBC hemolysis, suggesting that release of free peptide plays a role in membrane 
disruption. These studies also point out a potential source of inefficiency. Particle disassembly 
and hemolysis begin at a pH of 5.5, before siRNA is completely released at a pH of 4.5. If 
endosomal disruption occurs before complete siRNA release from p5RHH, not all of the 
delivered siRNA will be accessible to the RISC. This possibility necessitates a more detailed 
biophysical characterization of siRNA release from p5RHH/siRNA nanoparticles. Nonetheless, 
it is clear that p5RHH demonstrates a key characteristic required for efficient cytoplasmic 
delivery of siRNA: the ability to coordinate siRNA release with concurrent endosomal 
disruption. 
Histidine protonation has often been used as a trigger for siRNA delivery in the context 
of the proton sponge effect, in which various strategies have taken advantage of histidine’s 
buffering capacity to neutralize endosomal acidification, leading to osmotic rupture of the 
endosome due to the accumulation of Cl- counterions.32, 40-44 Moreover, histidine appears to be an 
ideal buffering agent due to a lack of pKa changes when non-specifically associated with nucleic 
acids.45 While p5RHH also relies on histidine protonation as a trigger for siRNA release, the 
mechanism of endosomal escape appears to be direct membrane lysis rather than osmotic 
disruption. In comparison with methods relying on endosomal buffering for osmotic rupture, the 
presence of only two histidine residues in our peptide suggest that p5RHH does not have the 
buffering capacity to rely on the proton sponge effect for endosomal escape. As an example, Lo 
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and Wang have shown that at least ten histidine residues are required for successful cytoplasmic 
release of DNA when transfected by TAT.32  
While we cannot completely rule out a contribution of the proton sponge effect to the 
endosomolysis seen via acridine orange release, our data indicate that endosomal acidification 
triggers particle disassembly and release of membrane-lytic peptide to promote endosomolysis. 
The unique ability of p5RHH/siRNA nanoparticles to efficiently coordinate these events 
portends potential for the use of p5RHH-mediated transfection in a variety of cell types. 
Furthermore, analysis of p5RHH’s mechanism of action provides insight that can guide the 
further development of future peptide vectors for siRNA transfection. 
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Chapter 4 
Therapeutic Potential for Melittin-Derived siRNA Nanocarriers 
 
4.1 Abstract 
 Despite the many diseases potentially treatable by siRNA therapeutics, the clinical 
application of siRNA to the treatment of disease is effectively limited by nanoparticle 
pharmacokinetics. Due to poor extravasation through continuous endothelium, penetration of 
siRNA-carrying nanoparticles into most diseased tissues is severely limited, suggesting that only 
vascular/hematologic diseases or diseases characterized by disrupted endothelial barriers can be 
targeted with current siRNA delivery technology. Such diseases include tumors, sites of 
angiogenesis, atherosclerosis, and leukemia. Initial studies regarding siRNA delivery in relevant 
tissue culture models indicate that p5RHH is able to safely and efficiently mediate siRNA 
transfection in multiple cell types that are traditionally considered to be difficult to transfect. 
These cell types include primary human umbilical vein endothelial cells, macrophages, and 
lymphocytes. In most cell types, comparison with Lipofectamine 2000 indicates that p5RHH is 
less effective, but p5RHH is equally potent when transfecting the RAW264.7 macrophage cell 
line. The potential utility of siRNA is best illustrated in the therapy of HTLV-1-induced ATLL in 
which NFκB activation has been shown to mediate immortalization. Due to the complexity of 
NFκB signaling, small molecule inhibitors have only been able to block its activation but not its 
action. Given the complicated nature of NFκB activation in vivo, these small molecules may be 
of limited utility, highlighting a need for new therapeutics. Initial studies using p5RHH/siRNA 
nanoparticles reveal the ability to simultaneously transfect p65 and p100/p52 siRNAs into a 
model of ATLL leading to blockade of both canonical and non-canonical NFκB signaling for a 
strong suppression of ATLL viability. Initial in vivo studies suggest that p5RHH is able to 
localize to ATLL tumors in a spontaneous murine model of the disease with clearance mediated 
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by the kidneys. These initial data are suggestive of potential for tumor suppression, warranting 
further in vivo characterization of p5RHH/siRNA nanoparticle stability and efficacy. 
 
NOTE: Portions of this chapter are adapted from previously published work. 
Hou, K.K.; Pan, H.; Lanza, G.M.; Wickline, S.A., Melittin derived peptides for nanoparticle 
based siRNA transfection. Biomaterials 2013, 34 (12), 3110-3119.   
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4.2 Introduction 
 From a theoretical standpoint, siRNA has the potential to be useful in a variety of 
diseases, most notably cancer, inflammation and atherosclerosis, where pathology can be 
attributed to a handful of specific proteins. Unfortunately, the utility of siRNA in clinical 
situations is limited by poor biodistribution as a consequence of their packaging into 
nanoparticles. While nanoparticles are expected to improve circulation half-lives and enable 
targeted delivery to diseased tissues, these drug delivery paradigms are difficult to achieve in 
practice. In reality, the tissue distribution of nanoparticle therapeutics is not determined by 
targeting ligands on their surface, but by vascular architecture and cellular composition. 
 For example, nanoparticles tend to deposit in the organs of the reticulo-endothelial 
system (RES), which includes the liver, spleen, and bone marrow. Based on the specialization of 
their vascular architecture, sinusoids in the spleen and bone marrow filter and capture 
nanoparticles larger than 200 nm. On the other hand, fenestrae in the liver endothelium allow 
particles less than 100 nm to pass through and enable hepatocyte or macrophage uptake.1 While 
tissue architecture often determines nanoparticle accumulation, nanoparticle uptake is 
determined by cellular composition. For instance, macrophages in the spleen, lung, and liver tend 
to phagocytose the majority of nanoparticles deposited in those tissues due to their natural 
function in clearance of cellular debris and extracellular pathogens. Interestingly, active targeting 
of nanoparticles by incorporating targeting moieties on the nanoparticle surface has been shown 
to improve uptake into desired cells after extravasation, although active targeting does not affect 
biodistribution and tissue accumulation.2 
Based on these findings, it is clear that pathologies targetable by siRNA-carrying 
nanoparticles must occur in the blood stream or exhibit a discontinuous endothelial barrier to 
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allow nanoparticles to escape the vasculature and enter the tissue. In this chapter, we establish 
proof of concept for the utility of p5RHH/siRNA nanoparticles in the treatment of such diseases. 
Examples include solid tumors, which are often invested by newly formed blood vessels 
characterized by poorly formed basement membranes and a lack of supporting pericytes, states 
of severe atherosclerosis, which are characterized by discontinuous endothelial barriers, 
inflammatory conditions in which angiogenic vessels participate in disease progression, and 
hematologic malignancies such as leukemia.3, 4 
 
4.3 Materials and Methods 
4.3.1 Cell Culture 
B16-F10 and RAW264.7 (ATCC, Manassas, VA) cell lines were maintained under 
standard cell culture conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco). F8 cells from the Ratner lab 
were maintained in 10% RPMI (Gibco). Human umbilical vein endothelial cells (HUVECs) were 
purchased from Lifeline Technologies (Frederick, MD) and cultured in VascuLife Basal Medium 
(Lifeline Technologies) supplemented with 5 ng/mL EGF, 5 ng/mL bFGF, 15 ng/mL IGF-1 , 50 
µg/mL ascorbic acid, 1 µg/mL hydrocortisone hemisuccinate, 0.75 U/mL heparin sulfate, 10 mM 
L-glutamine, and 2% fetal bovine serum in accordance with manufacturer instructions. For all 
experiments, HUVECs were used at passage three. 
4.3.2 siRNA Transfection 
Cells were plated in 6-well plates 12 hours before transfection and cultured under 
standard cell culture conditions. p5RHH/siRNA nanoparticles were prepared and incubated with 
cells for 4 hours in a final volume of 1 mL Optimem I (Gibco) or appropriate media 
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supplemented with 10% FBS. Transfections were scaled accordingly for cells plated in 12-well 
plates based on cell culture surface area. After transfection, cells were washed twice with PBS 
and incubated with standard cell culture medium for another 24 to 72 hours before analysis. 
Lipofectamine 2000 was used in accordance with the manufacturer’s protocol. siGENOME 
mouse MAPK9 siRNA1, siGENOME mouse STAT3 siRNA2, siGENOME human STAT3 
siRNA2, siGENOME mouse NFΚB (p65) siRNA5, and siGENOME mouse NFΚB2 (p100/p52) 
siRNA1 were purchased from Dharmacon (Lafayette, CO). Scrambled siRNA was purchased 
from Qiagen (Valencia, CA). 
4.3.3 Western Blotting 
24 or 48 hours after transfection, 100 to 200 µL RIPA buffer (10 mM Tris–HCl (pH 7.5), 
150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
1 mM EDTA, 5% glycerol) with 1 mM PMSF and Complete Protease Inhibitor Cocktail (Roche) 
was added to each well of a 6-well plate and incubated on ice for 1 hour. Cell lysates were then 
centrifuged at 4˚C for 5 minutes and supernatants stored at -20˚C. Lysates were resolved on 
Nupage Bis-Tris gels (Life Technologies) and transferred to 0.22 µm nitrocellulose before 
blocking in 5% bovine serum albumin (Sigma) in TBS-T. Primary antibodies used included 
rabbit anti-GAPDH (1:1,500, Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-β-actin 
(1:1,000, Sigma), mouse anti-STAT3 (1:1,000, Cell Signaling, Danvers, MA), rabbit anti-JNK2 
(1:1,000, Cell Signaling), rabbit anti-p65 (1:1,000, Cell Signaling), rabbit anti-p100 (1:1,000, 
Cell Signaling). Secondary antibodies used included anti-rabbit HRP (1:5,000, Santa Cruz 
Biotechnology) and anti-mouse HRP (1:5,000, Santa Cruz Biotechnology). Blots were developed 
using ECL Western Blotting Substrate (Pierce, Rockford, IL). Representative western blots are 
presented herein. 
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4.3.4 Real-Time PCR 
24 hours after transfection, cDNA was produced using the FastLane Cell cDNA kit 
(Qiagen). cDNA was stored at -20˚C until use. mRNA levels were quantified on an Applied 
Biosystems 7300 System (Applied Biosystems, Carlsbad, CA) using iTaq SYBR green with 
ROX (Bio-Rad, Hercules, CA). Quantitect Primer Assay (Qiagen) provided gene-specific 
primers for each gene. Genes of interest were normalized to species-appropriate β-actin. Results 
are reported as the average “fold change” relative to untreated controls for three separate 
experiments. 
4.3.5 Cell Viability Assay 
Cell viability was determined 72 hours post-transfection using Alamar Blue (Life 
Technologies). Briefly, Alamar Blue was diluted 1 to 10 into phenol red-free media and 
incubated with cells for 2 to 4 hours. Fluorescence was measured on a fluorescent plate reader 
with excitation at 570 nm and emission at 585 nm (Varian Cary Eclipse, Agilent Technologies, 
Santa Clara, CA). 
4.3.6 Tube Formation Assay 
Matrigel (BD Biosciences, San Jose, CA) was thawed overnight at 4˚C in an ice bath and 
subsequently allowed to gel in 24-well plates for 1 hour at 37˚C. 24 hours after transfection with 
STAT3 specific or control siRNA, HUVECs were trypsinized and plated on matrigel at a cell 
density of 30,000 cells/well. Tube formation was allowed to proceed for 24 hours before 
visualization on an inverted microscope. A tube formation score was determined based on total 
tube length per field of view normalized to untreated controls as measured in ImageJ (NIH). 
4.3.7 HUVEC Migration Assay 
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The bottoms of 12-well transwell inserts with 3.0 µm pore size (Corning, Tewksbury, 
MA) were coated with 1% porcine gelatin (Sigma) at room temperature for 1 hour. HUVECs 
transfected with STAT3 specific or control siRNA 24 hours in advance were then trypsinized 
and resuspended in growth factor-free media and added to the apical transwell chamber at a 
density of 30,000 to 50,000 cells/well. The bottom chamber contained growth factor-free 
VascuLife basal media ± 5 ng/mL bFGF. Cells were allowed to migrate through the polymer 
insert for 12 hours. Un-migrated cells were removed from the apical chamber with a sterile 
cotton swab, and migrated cell numbers were determined via Alamar Blue. Data are presented as 
the average normalized migration from 3 separate experiments. For visualization, inserts were 
cut out and mounted on glass slides. Cell nuclei were visualized with DAPI staining on an 
Olympus BX610 (Tokyo, Japan) and reported as average cell number per field of view. 
4.3.8 Foam Cell Formation Assay/Oil-Red O Staining 
48 hours after transfection with JNK2 specific or control siRNA, RAW264.7 cells were 
incubated ± 50 µg/mL Ac-LDL (Intracel, Frederick, MD) for an additional 24 hours. Cells were 
then stained with Oil-Red O to visualize foam cell formation. Briefly, Oil-Red O was dissolved 
in neat methanol (5 mg/mL) overnight before filtration through a 0.22 µm filter. The Oil-Red O 
stock was then diluted 3 to 5 in distilled water to make up the Oil-Red O working solution and 
filtered a second time through a 0.22 µm filter. Cells were fixed in 4% PFA for 10 minutes at 
room temperature and washed with 60% methanol before staining in the Oil-Red O working 
solution for 15 minutes. After staining, cells were washed once with 60% methanol and once 
with distilled water before mounting on glass slides. 
4.3.9 Animal Experiments 
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Experimental animal protocols were approved by the Animal Care Committee of 
Washington University School of Medicine. Transgenic mice with spontaneous tumors were a 
gift from the Ratner lab.5 Mice with advanced tumors were selected for pilot experiments and 
injected with a single dose at 1 mg/kg 24 hours before sacrifice. Animals were perfused with 
saline, and tumors were excised for IVIS imaging and frozen sectioning.  
 
4.4 Results 
4.4.1 STAT3 siRNA Delivery to Slow Melanoma Growth 
Signal Transducer and Activator of Transcription 3 (STAT3) is a well-known oncogene 
believed to play a critical role in a wide variety of human malignancies.6, 7 To test the ability of 
p5RHH to knockdown constitutively activated oncogenes, we targeted STAT3 expression in 
B16-F10 cells which are known to be STAT3 dependent.8 Delivery of a STAT3-specific siRNA 
led to degradation of STAT3 mRNA with a subsequent decrease in STAT3 protein levels 
(p5RHH IC50: ~50 nM, Lipofectamine 2000 IC50: ~10 nM) (Figure 4.1). p5RHH-mediated 
STAT3 siRNA transfection led to decreased B16-F10 viability (60% at 200 nM) 72 hours 
following transfection as determined by Alamar Blue assays (Figure 4.1f). Importantly, 
scrambled siRNA showed no effect on B16-F10 viability, illustrating the safety of p5RHH in 
comparison to Lipofectamine 2000 (Figure 4.1c), which produced an equivalent decrease in cell 
viability (up to 60% at 200 nM) when delivering either STAT3-specific or scrambled siRNAs, 
highlighting the improved cytotoxicity profile provided by p5RHH. 
4.4.2 STAT3 siRNA Delivery to Decrease Angiogenesis 
Pathological angiogenesis is a hallmark of many disease states, including cancer, 
atherosclerosis, and inflammation. STAT3 has previously been shown to be a key mediator in the 
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Figure 4.1 Knockdown of STAT3 in B16-F10 Cells 
Lipofectamine mediates STAT3 knockdown with an IC50 of 10 nM as determined by western blotting (a) 
and RT-PCR (b) but is unable to mediate a STAT3-specific decrease in cell viability due to non-specific 
cytotoxicity (c). p5RHH mediates sequence-specific knockdown of STAT3 with an IC50 of 50 nM as 
determined by western blotting (d) and RT-PCR (e) resulting in a STAT3-dependent decrease in cell 
viability 72 hours post-transfection (f). 
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migration and maturation of endothelial cells during angiogenesis.9-12 Therefore, we delineated 
the ability of p5RHH to deliver STAT3 siRNA to HUVEC cells for the blockade of angiogenesis 
in vitro with the use of matrigel tube formation assays and transwell cell migration assays. 
HUVECs transfected with p5RHH/STAT3 siRNA nanoparticles exhibited a decrease in STAT3 
mRNA and protein levels with an IC50 of ~50 nM (Figure 4.2d,e) without any accompanying 
decrease in HUVEC viability (Figure 4.2f). As with transfection of B16-F10 cells, 
Lipofectamine 2000-mediated transfection exhibits an IC50 of ~10 nM by western blotting but 
causes cytotoxicity with a 40% decrease in cell viability at siRNA doses as low as 25 nM (Figure 
4.2a-c).  
Although p5RHH-mediated STAT3 siRNA transfection did not impact cell viability, 
p5RHH/STAT3 siRNA nanoparticle treatment of HUVECs manifested a ~60% decrease in tube 
formation as compared to scrambled siRNA (Figure 4.3a,b). In addition, migration of HUVECs 
transfected by p5RHH was reduced by 50% as quantified by Alamar Blue (Figure 4.3d) and 
fluorescence microscopy (Figure 4.3c). These data demonstrate the high efficiency with which 
p5RHH is able to safely transfect primary human endothelial cells for the prevention of 
pathological angiogenesis.  
4.4.3 JNK2 siRNA Delivery to Decrease Foam Cell Formation 
The disrupted endothelial barriers that characterize atherosclerotic plaques make 
atherosclerosis a prime target for nanoparticle-based therapies.13 To ensure that we could use 
p5RHH/siRNA nanoparticles to block foam cell formation, the hallmark of atherosclerotic 
plaques, we delivered JNK2 siRNA to RAW264.7 (mouse macrophage cell line) in vitro. JNK2 
is a known mediator of foam cell formation and has been implicated in the uptake of both Ac- 
LDL by scavenger receptor A as well as oxLDL by CD36.14, 15 p5RHH was able to deliver 
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Figure 4.2 Knockdown of STAT3 in HUVECs 
Lipofectamine mediates STAT3 knockdown with an IC50 of 10 nM as determined by western blotting (a) 
and RT-PCR (b) but induces nonspecific cytotoxicity (c). p5RHH mediates sequence-specific knockdown 
of STAT3 with an IC50 of 50 nM as determined by western blotting (d) and RT-PCR (e) without 
cytotoxicity (f). 
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Figure 4.3 STAT3 Knockdown in HUVECS Decreases Angiogenesis in vitro 
STAT3 siRNA decreases tube formation on matrigel by 60% (scale bar = 200 µm) when compared to 
controls (a) as quantified by tube formation score (b). STAT3 siRNA transfection also yields a 40% 
decrease in HUVEC migration in response to bFGF in transwell migration assays as determined by 
microscopy (scale bar = 50 µm) (c) and Alamar Blue assays (d). * p < 0.05 
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Figure 4.4 JNK2 Knockdown in Macrophages Decreases Foam Cell Formation 
Lipofectamine 2000 decreases JNK2 expression with an IC50 of 10 nM (a) but causes significant 
cytotoxicity when transfecting scrambled siRNA (b). p5RHH-mediated transfection has an IC50 of 10 
nM (c), leading to a JNK2-specific decrease in RAW264.7 viability (d). Knockdown of JNK2 by 
p5RHH/siRNA nanoparticles at a final siRNA concentration of 50 nM (e) shows a strong decrease in 
lipid droplet accumulation in RAW264.7 cells compared with cells treated with scrambled siRNA or 
untreated controls. (Scale bar = 25 µm) 
 
siRNA to RAW264.7 cells, leading to a strong decrease in JNK2 protein levels at concentrations 
as low as 10 nM (Figure 4.4c). Notably, JNK2 siRNA slowed RAW264.7 proliferation rates 
while scrambled siRNA had no affect on cell proliferation (Figure 4.4d). In comparison, 
Lipofectamine 2000 has a similar IC50 as determined by western blotting (Figure 4.4a) but also 
exhibits extensive cytotoxicity (Figure 4.4b). These data show that transfection of RAW264.7 
cells by p5RHH appears to be on par with the transfection achieved by Lipofectamine 2000 
without the noted cytotoxicity.  
Decreased JNK2 protein levels suppressed foam cell formation in RAW264.7 cells that 
were incubated in the presence of 50µg/mL Ac-LDL for 12 hours as determined by light 
microscopy following Oil-Red O staining (Figure 4.4e). These images show extensive lipid 
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droplet accumulation in non-treated controls and scrambled siRNA treated cells but no lipid 
droplet accumulation in RAW264.7 cells treated with a JNK2-specific siRNA. 
4.4.4 siRNA Delivery to Block NFκB Signaling in ATLL 
The F8 model of HTLV-1-induced ATLL provided a cell line of lymphocytic origin, 
which has previously been characterized to show a strong dependence on constitutive activation 
of both canonical and non-canonical NFκB pathways similar to human disease. siRNAs were 
chosen to target the p65 subunit of the canonical pathway and p100/p52 subunit of the non-
canonical pathway. Western blotting revealed a dose-dependent decrease in the expression of 
both proteins that was not seen when cells were transfected with a scrambled siRNA control 
(Figure 4.5a,b). 
Alamar Blue assays 48 hours post-transfection suggest that knockdown of these pathways 
in vitro is therapeutically relevant, as a strong decrease in cell viability is recorded with both p65 
and p100/p52 siRNAs (Figure 4.5c). However, it is clear that blockade of the non-canonical 
NFκB pathway with p100/p52 siRNA (IC50 ~100 nM) is superior to blockade of the canonical 
pathway (IC50 ~200 nM). Interestingly, when particles were prepared carrying both p65 and 
p100/p52 siRNAs together, a synergistic effect on cell viability was recorded (IC50 ~50 nM).  
Given the safety of p5RHH in tissue culture, pilot experiments were conducted to 
examine tumor localization of p5RHH/siRNA nanoparticles when delivered in vivo. IVIS 
imaging and confocal microscopy reveal tumor delivery of Cy5.5-labeled scrambled siRNA 
(Figure 4.6) when introduced by tail-vein injection into mice carrying spontaneous ATLL tumors 
at a dose of 1 mg/kg. Notably, after 24 hours, no siRNA was seen in traditional clearance organs 
such as the liver and spleen, but strong uptake was found in the kidneys (Figure 4.6b). Confocal 
microscopy indicates that Cy5.5-siRNA was taken up in the proximal tubules (Figure 4.6f). 
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Figure 4.5 NFκB Blockade Decreases ATLL Viability 
(a, b) Western blotting demonstrates knockdown of p100/p52 and p65. (c) Alamar Blue assays 48 hours 
post-transfection reveal that scrambled siRNA (■) does not affect F8 cell viability. Knockdown of the p65 
pathway (▲) has an IC50 of nearly 200 nM. Targeting p100/p52 (●) yields an IC50 of 100 nM. 
Simultaneous blockade of both NFkB pathways (u) improves the IC50 to 50 nM.  
 
Figure 4.6 p5RHH Delivers Cy5.5-Labeled siRNA to Tumors and Kidneys 
(a,b) Ex vivo IVIS imaging of resected organs indicates delivery of Cy5.5-labeled siRNA to tumors and 
kidneys 24 hours after injection at a dose of 1 mg/kg. (c-f) Confocal microscopy confirms siRNA delivery 
to the periphery of the tumor (e) as well as the proximal tubules of the kidney (f). (Scale bar = 50 µm) 
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4.5 Discussion 
Given the size of our nanoparticles (50 to 200 nm), we have targeted disease processes 
that do not require vascular extravasation through intact endothelial barriers. Cancer, 
angiogenesis, and atherosclerosis are all characterized by a discontinuous endothelial barrier with 
enhanced leakage of nanoparticles into the surrounding tissues. Towards the goal of establishing 
a basis for future in vivo studies, we have successfully knocked down STAT3 in melanoma cells, 
STAT3 in primary endothelial cells, JNK2 in macrophages, and p65 or p100/p52 in ATLL cells 
with minimal cytotoxicity. Despite robust transfection in all cells, transfection efficiency appears 
to vary by cell type. RAW264.7 macrophages are the easiest to transfect with an IC50 of 25 nM. 
Differences in transfection efficiency among cell types is likely partially attributable to variation 
in the native ability of each cell to perform macropinocytosis. Given their propensity for fluid 
phase uptake as part of their normal function, macrophages likely take up an increased amount of 
p5RHH/siRNA nanoparticles compared to other cell types. 
Of equal importance is the observation that all tested doses resulted in minimal 
cytotoxicity. The safety of p5RHH/siRNA nanoparticles in all tested cell types indicates that 
vector-induced toxicity is unlikely to hinder the use of p5RHH in animal studies. Moreover, 
p5RHH/siRNA nanoparticles also exhibit size stability and improved siRNA transfection 
capacity when incubated in the presence of human serum albumin for 24 hours before 
transfection, an issue which has been acknowledged to diminish the activity of some CPP 
transfection agents.16 Although detailed siRNA protection and long-term stability analysis 
remains to be performed, these data further suggest that p5RHH/siRNA nanoparticles might 
provide therapeutic benefits when utilized for transfection in vivo. 
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The use of siRNA as a therapeutic allows the treatment of disease through targeted 
therapies based on a patient’s specific disease. By leveraging prior knowledge about the genomic 
aberrations that contribute to disease pathologies, the efficacy of disease treatment can be 
improved. For example, ATLL is driven by activation of both the canonical and non-canonical 
NFκB pathways. As reviewed by Rauch and Ratner, the non-canonical pathway plays a larger 
role in promoting anti-apoptotic protein expression than the canonical pathway, marking it as the 
more highly desirable target for affecting the proliferation of ATLL cells.17 Our data utilizing 
p5RHH-mediated siRNA delivery not only confirm this hypothesis but also reveal a synergistic 
response when targeting both the canonical and non-canonical NFκB pathways with a single 
p5RHH-based nanoparticle which simultaneously packages both p65 and p100/p52 siRNAs. 
These results are important for the future treatment of ATLL given published results 
questioning the efficacy of small molecule inhibitors of NFκB activation. In comparison with 
currently available small molecule inhibitors of NFκB activation such as PS-341 (a proteasome 
inhibitor) and Bay11-7082 (an IKK inhibitor), our approach provides direct inhibition of NFκB 
through decreased NFκB subunit expression. The uncertainty surrounding the mechanism of 
NFκB activation in ATLL cells suggests that direct downregulation of NFκB protein levels is the 
most efficacious approach for inhibiting the anti-apoptotic mechanisms driven by NFκB 
signaling.18  
Initial studies in a spontaneous model of ATLL demonstrate that a single dose of siRNA 
is enough to allow siRNA delivery into the tumor as imaged by ex vivo fluorescence imaging and 
confirmed by confocal microscopy. Although siRNA appears to be limited to the tumor 
periphery, ongoing work will include future experiments to determine if siRNA is able to enter 
malignant cells, which appear to concentrate at the periphery of the tumor (Rausch, unpublished 
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observations). Interestingly, IVIS imaging also demonstrates kidney localization of the particle 
with minimal spleen or liver uptake. While the size of our nanoparticles would suggest minimal 
kidney filtration into the urine, it appears that the kidneys are a primary source of clearance for 
our nanoparticles. While further examination of p5RHH/siRNA nanoparticles is required in this 
context, polyplexes and lipidic transfection agents have been shown to disassemble in the 
glomerulus due to electrostatic competition for vector binding by the negatively charged 
proteoglycans that make up the glomerular basement membrane. The liberated siRNA is then 
filtered into the urine, where a portion is reabsorbed by the proximal tubule cells leading to 
apparent kidney-specific localization.19 
Despite this potential clearance mechanism, the use of p5RHH to mediate delivery 
appears to increase the circulation half-life of the siRNA as compared to free siRNA. When 
examining uptake of siRNA by proximal tubule cells in the kidney, naked siRNA was noted to 
clear the kidney by 24 hours post-injection. In contrast, our findings show clear siRNA 
localization to the kidney 24 hours after injection.20 In fact, future formulations with tuned 
dissociation in the glomerulus may prove beneficial as long-circulating pegylated liposomes 
have led to skin specific toxicities due to capillary deposition.21 By taking advantage of this 
clearance mechanism, the pharmacokinetics of the siRNA delivery agent can be tuned to avoid 
inappropriate biodistribution. 
Prior attempts to target NFκB expression itself have focused on the use of naked 
antisense DNA oligonucleotides or lentiviral shRNA expression, which has limited therapeutic 
potential.22, 23 The use of antisense oligonucleotides is inefficient, requiring an order of 
magnitude more therapeutic than our current siRNA formulation in vitro. On the other hand, 
viral vectors for shRNA expression have encountered a variety of challenges in human trials 
94 
 
ranging from induction of cancer to toxicity from saturation effects.24-26 We believe our initial 
studies offer proof of concept that the use of p5RHH for highly efficient low toxicity transfection 
of NFκB targeted siRNA may provide a therapeutically relevant strategy for the treatment of 
ATLL and other hematologic malignancies, warranting further in vivo studies. 
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Chapter 5 
Conclusions and Future Directions 
 
Successful application of siRNA as a therapeutic requires the development of vectors that 
can promote cytoplasmic delivery of siRNA without inducing cytotoxicity. Towards this end, 
short positively charged amphipathic peptides have demonstrated the ability to deliver siRNA 
without inducing cell death.1 Unfortunately, these methods yield suboptimal transfection 
efficiency due to endosomal entrapment. Nevertheless, due to their biodegradability and 
construction from naturally occurring amino acids, peptide vectors represent a promising class of 
siRNA vectors that is still in its infancy. The development of new peptide sequences holds 
promise for improved siRNA release in the cellular milieu. Furthermore, understanding the 
mechanism behind this release may provide a basis for further optimization of future peptides. 
To avoid the endosomal entrapment that plagues existing peptide transfection agents, we 
focused on peptides derived from melittin, the hemolytic component of honeybee venom. 
Changes to melittin include modifications designed to decrease cytotoxicity, improve 
electrostatic siRNA binding, and allow for pH triggered nanocomplex disassembly. Specifically, 
this work takes advantage of N-terminal truncation of melittin, which our lab has previously 
demonstrated to reduce melittin cytotoxicity by two orders of magnitude while retaining a 
propensity for partitioning into lipid bilayers. In addition, amino acids found at high 
concentration in DNA-compacting proteins such as protamine (arginine and histidine) are 
appended to the C-terminus for improved siRNA binding and release in response to acidic pH. 
In Chapter 2, melittin derivatives were screened for siRNA transfection. The physical 
characteristics of the nanocomplexes they formed when combined with siRNA were 
characterized, and their transfection efficiency was compared to standard lipid agents. After  
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Figure 5.1 Mechanism of Cytoplasmic siRNA Delivery by p5RHH 
p5RHH packages siRNA into nanoparticles 50 to 200 nm in diameter for cellular entry by 
macropinocytosis. Endosomal acidification drives particle disassembly with release of p5RHH to mediate 
endosomolysis. siRNA then accesses the cytoplasm to drive RISC assembly and mRNA degradation. 
 
screening seven melittin derivatives, four were found to be capable of siRNA transfection. The 
most active peptide, p5RHH is able to completely package siRNA at peptide to siRNA ratios 
greater than 50 to 1 to form nanocomplexes. Zeta potential and dynamic light scattering reveal 
that these complexes are stabilized by electrostatic repulsion with a particle size of 50 to 200 nm. 
Unfortunately, the low magnitude of the surface charge (+12 mV) leads to an unstable 
formulation with continued aggregation likely driven by hydrophobic interactions. This 
aggregation results in a size distribution with multiple populations, as confirmed by deep-etch 
electron microscopy. Continued aggregation leads to loss of transfection efficiency, pointing to 
the importance of particle stabilization for sustained siRNA transfection. Formulations stable for 
over 24 hours can be achieved by coating the nanoparticles with albumin. When compared to 
Lipofectamine 2000, p5RHH is less efficient with an IC50 between 25 to 50 nM depending on 
the cell type. Notably, p5RHH has limited vector-associated toxicity, as transfection with 
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scrambled siRNA does not alter cell viability at all tested doses. These findings indicate that the 
melittin derivative, p5RHH, is a safe and effective siRNA transfection agent with potential utility 
as a basic science research tool and as a clinically relevant therapeutic. 
Based on our examination of p5RHH’s mechanism of action in Chapter 3, p5RHH enters 
the cell by macropinocytosis as a component of p5RHH/siRNA nanoparticles, and is released 
upon exposure to acidic pH for endosomolysis by directly disrupting the endosomal membrane 
(Figure 5.1). Release of p5RHH occurs concurrently with siRNA release, a property that is 
critical for successful induction of RNAi. Comparison with non-functioning melittin derivative, 
p5RWR, demonstrates that an inability to release siRNA from the vector prevents GFP 
knockdown, even when endosomal escape is induced by incubation with endosomolytic agents 
which allows Cy3-labeled oligonucleotides to distribute throughout the cytoplasm. To assess the 
ability of p5RHH to mediate endosomal escape, chloroquine application, which was intended to 
potentiate endosomal escape, provided no additional benefit, revealing that p5RHH/siRNA 
nanoparticles are not trapped to any extent in the endosomes. To our knowledge, even the most 
efficient previously published peptide vectors have shown improvement upon treatment with 
chloroquine, implying some degree of endosomal entrapment.2  
We note that p5RHH does not provide exceptional transfection efficiency in vitro as 
compared with previously published peptide transfection agents. The most likely sources of 
inefficiency are incomplete siRNA release from the peptide vector and particle instability. Our 
data indicate that endosomolysis may occur before complete siRNA release, possibly limiting 
siRNA access to the RISC. A quantitative comparison of RISC-associated siRNA to total siRNA 
delivered is required to address this potential source of inefficiency. Furthermore, a more 
detailed characterization of the type of endocytic vesicles encountered during intracellular 
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processing and delineation of the exact point of endosomal escape may allow fine-tuning of 
particle disassembly to match the environmental triggers available along the endosome/lysosome 
pathway.3, 4 Additionally, it is likely that not all siRNA included in the formulation is delivered 
to cells. It is possible that some of the larger aggregates may sequester siRNA in an inactive 
fraction. These findings suggest that further analysis of the current formulation is required, 
including analysis of transfection efficiency as a function of nanoparticle size. Alternatively, new 
synthetic methods that entail two-phase formulation, such as solvent evaporation, potentially 
have utility in controlling particle size and promoting a more homogenous population of particles 
with uniform transfection capacity.5, 6 
Despite a heterogeneous particle size distribution, p5RHH/siRNA nanocomplexes exhibit 
considerable potential for the treatment of diseases characterized by endothelial dysfunction or 
diseases confined to the vascular compartment. As illustrated in Chapter 4, examples include 
solid tumors, angiogenesis, advanced atherosclerosis, and leukemia. Initial studies addressing the 
treatment of these diseases include knockdown of STAT3 in B16-F10 mouse melanoma cells, 
STAT3 in primary human umbilical vein endothelial cells, JNK2 in RAW264.7 mouse 
macrophages, and NFκB in F8 leukemia/lymphoma cells. Transfection efficiency varies by cell 
type with an IC50 as low as 25 nM in macrophages, a finding that may be attributable to the 
preference for p5RHH/siRNA nanoparticles to enter cells via fluid-phase uptake. Nevertheless, 
these data reveal a broad applicability for p5RHH in the transfection of many relevant cell types 
without significant cytotoxicity. The promising nature of p5RHH-mediated transfection and the 
observation of albumin stabilization of nanoparticle size suggest that direct injection of 
p5RHH/siRNA nanoparticles into the bloodstream can result in meaningful delivery of 
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p5RHH/siRNA nanoparticles to disease sites in vivo with particle stabilization induced by 
coating with native serum albumin.  
Initial studies examining delivery of p5RHH/siRNA nanoparticles to spontaneous tumors 
in a murine model of ATLL indicate delivery to the tumor periphery with uptake in the kidneys 
but no deposition in traditional clearance organs such as the liver or the spleen. Kidney 
accumulation may be an indication of an unknown mechanism of targeting to the proximal 
tubules of the kidney or possible p5RHH/siRNA nanocomplex disassembly on the glomerular 
basement membrane. A more careful analysis of p5RHH/siRNA biodistribution and 
pharmacokinetics is required to determine what percent of the injected dose is able to reach the 
tumor. In addition, achieving significant nanoparticle delivery to tumors in vivo may require 
additional strategies to modify vascular permeability or improve transcytosis to bypass vascular 
constraint by endothelial tight junctions. 
Melittin derivatives exhibit efficient siRNA transfection attributable to lysis of 
endosomal membranes without inducing cytotoxicity in vitro. In view of promising in vivo 
proof-of-concept studies, p5RHH/siRNA nanoparticles may exhibit utility in the treatment of 
many diseases. Ultimately, improved peptide-mediated transfection may require new peptides 
with enhanced siRNA-release characteristics or development of new formulation methods to 
increase particle homogeneity. Nevertheless, the data presented in this thesis demonstrate that 
melittin derivatives alone facilitate delivery of siRNA to the cytoplasm and suggest general 
guidelines that may serve to direct the development of new peptide vectors for improving the 
efficiency of siRNA therapeutics. 
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Appendix I 
Stimulation of Transvascular Transport for  
Improvement of Nanoparticle Biodistribution 
 
AI.1 Abstract 
 The intact endothelial barrier prevents extravasation of particles larger than 2 nm, 
effectively resulting in vascular constraint of nanoparticles. Fortunately, natural mechanisms 
such as caveolar transcytosis exist to improve transport of macromolecules including lipoprotein 
particles and albumin into the extravascular space. Existing work indicates that endothelial cells 
are specially adapted for transcytosis via increased expression of caveolar vesicles. 
Consequently, stimulating caveolar uptake may be an appropriate method of also increasing 
nanoparticle transcytosis by endothelial cells. To this end, we have tested lipid-conjugated 
peptides known to activate the signaling pathway controlling caveolar endocytosis as a method 
of increasing rates of transcytosis. The peptide myr-SIRK indirectly stimulates caveolin-1 
phosphorylation, an early step in caveolar uptake, but does not induce tight junction disassembly. 
When utilized for the stimulation of human umbilical vein endothelial cell (HUVEC) 
monolayers, myr-SIRK increases the transcytosis of albumin, a native cargo for caveolar 
transcytosis. Importantly, myr-SIRK also increases the fluid phase transport of 70 kDa dextran, a 
5 nm macromolecule, which has low native endothelial permeability, but not inulin, a small 
molecule whose transport is determined by paracellular diffusion. To determine the utility of this 
strategy in transcytosis of therapeutics, we also demonstrated that myr-SIRK can stimulate the 
transport of antibodies. We envision the future incorporation of this lipid-peptide construct into 
perfluorocarbon nanoparticles to enable tissue-targeted delivery of myr-SIRK for localized 
activation of endothelial transcytosis. 
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AI.2 Introduction 
 Nanoparticles are hypothesized to dramatically augment the efficacy of drug delivery by 
aiding the delivery of drugs to specific sites with minimal “off-target” delivery. Nonetheless, 
nanoparticles have not provided the revolutionary benefits that were expected. Based on data 
analyzing nanoparticle biodistribution, it is clear that vascular constraint of nanoparticles limits 
the ability to utilize nanoparticles as delivery vehicles to extravascular targets.1, 2 For example, 
computational work modeling IgG antibody (180 kDa) penetration of tumors suggests that use of 
these natural nano-structures is limited by vascular extravasation.3 When considering the 
parameters that determine antibody concentration in the tumor, the authors conclude that 
diffusion away from the vasculature is often much quicker than extravasation with antibody 
consistently remaining at a low concentration in the tumor. Even for antibodies with a maximal 
dimension of 15 to 20 nm, endothelial tight junctions with a spacing of 2 nm are a significant 
barrier blocking access to the extravascular space.4  
Consequently, the challenge of enabling widespread use of nanoparticle therapeutics in 
the clinical setting requires improved nanoparticle biodistribution to extravascular targets. 
Current techniques for improving nanoparticle delivery past the endothelial barrier rely on 
improving paracellular transport or actively targeting nanoparticles to caveolar markers in order 
to promote transcytosis.5 For example, an NIH symposium exploring the challenges of Enhanced 
Permeability and Retention (EPR) of nanoparticles in tumors suggests that increased 
nanoparticle delivery can be achieved via transient induction of hypertension to improve 
convective transport through discontinuous angiogenic vessels or decreased tight junction 
integrity through the use of bradykinin.6 These strategies have previously been shown to 
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augment therapeutic nanoparticle delivery but will also alter the vasculature on a systemic level, 
potentially causing harm to patients.7 
Using an alternative strategy, Schnitzer et al. have improved targeted delivery of 
nanoparticles into the extravascular space by conjugating antibodies targeted against caveolar 
markers to nanoparticle surfaces.8, 9 These antibodies increase association of nanoparticles with 
endothelial caveolae to promote direct nanoparticle transcytosis.10, 11 Additionally, by choosing 
tissue-specific caveolar markers, nanoparticles can be targeted for transcytosis across the 
vascular bed of specific organs, such as the lung.12 Unfortunately, the rate of transcytosis appears 
to vary depending on the tissue with tumor transcytosis (minutes-hours, unpublished data) 
occurring an order of magnitude slower than lung transcytosis (seconds).9 
In additional work, Ruoslahti et al. have focused on the development of “tumor 
penetrating peptides” based on the C-end Rule in which arginines at the C-terminal end of a 
peptide in the context of R/KxxR/K-OH are able to bind to neuropilin-1 on endothelial cells to 
promote increased extravasation of covalently attached nanoparticles or even free 
nanoparticles.13, 14 Although the authors opine that the mechanism responsible for increased 
nanoparticle extravasation is based on stimulation of active transcytosis, a more likely 
mechanism is an increase in paracellular transcytosis due to tight junction disassembly. 
Specifically, previous work has shown that antibodies that cause neuropilin-1 oligomerization 
can lead to vascular leakiness due to tight junction disassembly.15-17 From this standpoint, tumor 
penetrating peptides may actually be of limited utility for continued dosing, as prolonged 
vascular leakiness can cause intratumoral hypertension, decreasing vascular patency and slowing 
convection in the extravascular space.6, 18, 19 
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Based on these previously published strategies, it appears that tissue-specific activation of 
transcytosis may be an unexplored means of augmenting nanoparticle delivery into a tissue of 
interest via fluid phase transport. Such a strategy would be analogous to tumor specific induction 
of paracellular transport by tumor-penetrating peptides without the concomitant increase in 
vascular leakiness. Moreover, these strategies can also augment the delivery of nanoparticles 
targeted to caveolar markers. To achieve this goal, lipid-conjugated peptides known to increase 
the rate of caveolar endocytosis are leveraged to stimulate direct transcytosis in HUVEC 
monolayers.20 
The cellular signaling involved in caveolar endocytosis is complex; however, detailed 
characterization of albumin transcytosis indicates that albumin binding to its cell surface receptor 
activates caveolin-1 and dynamin phosphorylation downstream of inhibitory G-protein coupled 
receptor activation.20, 21 Notably, Gi signaling can be directly stimulated by introduction of 
peptides with the sequence SIRKALNILGYPDYD into the cytoplasm of a cell.22, 23 Use of cell 
permeable myristoylated-SIRK leads to increased albumin uptake in cultured cells, but the 
ability of these myristoylated peptides to directly stimulate transcytosis in endothelial 
monolayers has not been established.20 Our work indicates that myr-SIRK not only increases 
transcytosis of native caveolar cargo but also increases fluid phase transport of cargos such as 
dextran and antibodies, which suggests the ability to increase nanoparticle transport as well. 
These peptides have the potential to be incorporated into perfluorocarbon (PFC) nanoparticles 
that can serve as a platform to directly deliver transcytosis stimulating lipid-peptide constructs to 
inflamed or angiogenic vasculature by utilizing targeting ligands for VCAM-1 or αυβ3. 
 
AI.3 Materials and Methods 
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AI.3.1 Synthesis of myr-SIRK 
SIRK was synthesized using FMOC chemistry on a CS Bio C5136 (Menlo Park, CA) and 
conjugated to myristic acid (Sigma, St. Louis, MO). myr-SIRK was purified by reversed-phase 
HPLC and dried by lyophilization. 
AI.3.2 HUVEC Culture and Monolayer Preparation 
Human umbilical vein endothelial cells (HUVECs) were purchased from Lifeline 
Technologies (Frederick, MD) and cultured in VascuLife Basal Medium (Lifeline Technologies) 
supplemented with 5 ng/mL EGF, 5 ng/mL bFGF, 15 ng/mL IGF-1, 50 µg/mL ascorbic acid, 1 
µg/mL hydrocortisone hemisuccinate, 0.75 U/mL heparin sulfate, 10 mM L-glutamine, and 2% 
fetal bovine serum in accordance with manufacturer instructions. For all experiments, HUVECs 
were used at passage three. For preparation of monolayers (Figure AI.1), 24-well transwell 
inserts (0.8 µm pore size PET membranes, BD Falcon, Franklin Lakes, NJ) were coated with 300 
µL 1% gelatin (2% porcine gelatin stock (Sigma, St. Louis, MO) diluted 1 to 2 with sterile H2O) 
for 30 minutes, followed by cell seeding at a density of 50,000 cells/well in 350 µL HUVEC 
media supplemented with antibiotics. The bottom chamber received 1.5 mL of HUVEC media 
supplemented with antibiotics. Media was changed every other day by removing the media in the 
cup, then the media in the well with the media in the well replaced first. 
 
 
Figure AI.1 HUVEC Monolayer Culture 
HUVECS are cultured in a monolayer on gelatin-coated PET membranes with a pore size of 0.8 µm. 
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AI.3.3 Monolayer Resistance Measurements 
 Monolayer measurements were performed using an Endohm-6 electrode (World 
Precision Instruments, Sarasota, FL). Briefly, the electrode and cup were sterilized with ethanol 
and allowed to dry. 1.5 mL HUVEC media with antibiotics was transferred to the electrode cup. 
Transwell inserts were transferred to the cup and resistance was measured, taking care to avoid 
air bubbles between the transwell insert and the bottom of the cup. Measurements were taken 
every other day to follow monolayer formation. Monolayers were considered complete when 
resistance reached ~44 Ω. 
AI.3.4 Caveolin-1 Western Blotting 
HUVECs were cultured in 6-well plates at 200,000 cells/well for 24 hours in HUVEC 
basal media without supplements or FBS. HUVECs were then stimulated with 1 to 10 µM myr-
SIRK, DMSO control, or full HUVEC media as a positive control. Cells were then washed with 
ice-cold PBS without Ca+2/Mg+2 and lysed with RIPA buffer at the indicated time points. Cell 
lysates were collected and stored at -80°C before resolution by polyacrylamide gel 
electrophoresis on a 10% Bis-Tris gel (Lifeline Technologies, Frederick, MD). After transfer to 
0.22 µm nitrocellulose, membranes were first probed for phospho-Caveolin-1 using rabbit anti-
pCav-1 polyclonal antibody (1:1,000, Cell Signaling) and subsequently stripped and re-probed 
for Caveolin-1 (rabbit polyclonal, 1 to 1,000, Cell Signaling). GAPDH was probed as a loading 
control. 
AI.3.5 Transcytosis Stimulation 
HUVECS were cultured on transwell inserts as described above. After monolayers were 
confluent (~1 week), media in the apical chamber was replaced with full HUVEC media 
supplemented with antibiotics containing either FITC-inulin (15 nM, Sigma), FITC-albumin (1.5 
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nM, Sigma), 70 kDa FITC-dextran (3 nM, Sigma) or Cy3 Goat-anti-Mouse IgG (75 µg/mL, 
Jackson Immuno Research, West Grove, PA). Cells were stimulated with either DMSO or 1 to 
100 µM myr-SIRK. Transport controls included 1-hour pretreatment of cells with 0.1% Triton-X 
to remove all cells or 10 mM EGTA to remove tight junctions. Transwell resistance was 
measured to ensure complete removal of cells by Triton-X treatment. 100 µL of media from the 
bottom well was removed at the indicated time points and the fluorescence was measured in a 
96-well plate. Each experiment included three replicates. Data are presented as an average from 
three separate experiments. 
AI.3.6 Direct Transcytosis 
HUVECs were seeded on transwell membranes with media changed every other day for 1 
week. Cells were then incubated in 1.5 nM FITC-albumin at 4°C for 30 minutes. After the 
incubation, cells were washed with ice-cold PBS three times and reintroduced to the tissue 
culture incubator. FITC-Albumin transcytosis at 40 minutes and 2 hours was recorded by 
removing 100 µL for fluorescence measurements. 
 
AI.4 Results 
AI.4.1 Stimulation of Caveolin-1 Phosphorylation 
 According to studies investigating albumin transport, activation of caveolin-1 is required 
for the caveolar endocytosis. To determine if myr-SIRK could directly stimulate this process, 
HUVECs were stimulated with 1, 2.5, and 10 µM myr-SIRK. Western blotting demonstrates that 
Caveolin-1 phosphorylation begins as soon as 15 minutes and continues for up to 1 hour at 10 
µM myr-SIRK (Figure AI.2). Notably, caveolin-1 phosphorylation is higher when stimulating 
with myr-SIRK than with HUVEC media containing growth factors and 10% FBS. 
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Figure AI.2 myr-SIRK Stimulates Caveolin-1 Phosphorylation 
Western blotting confirms stimulation of Caveolin-1 phosphorylation by 15 minutes, lasting for up to 60 
minutes. 
 
AI.4.2 No Adverse Effects on HUVEC Monolayer Integrity 
To determine if myr-SIRK negatively impacts tight junction integrity, the transwell 
resistance of myr-SIRK stimulated HUVEC monolayers was measured (Figure AI.3a). Triton-X 
treatment decreased resistance to 22 Ω, the same as unused new transwell inserts. Gelatin coating 
did not increase resistance (unpublished observations). Treatment with EGTA indicates that a 
transwell resistance of 32 Ω is attributable to cells alone with a further 10 Ω attributable to tight 
junction formation, in accordance with previously published values.24 These data also reveal that 
DMSO and 10 µM myr-SIRK do not affect tight junction formation, suggesting that any increase 
in transwell transport is attributable to active transcytosis by the cells and not due to increased 
paracellular diffusion. 
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Figure AI.3 myr-SIRK Stimulation Increases Caveolar Transcytosis 
(a) Transwell resistance measured 2 hours after myr-SIRK stimulation reveals tight junction integrity 
remains intact. (b) myr-SIRK stimulates transcytosis of prebound albumin. (c-e) myr-SIRK stimulates an 
increase in albumin and dextran transport but not inulin. 
 
AI.4.3 Increased Transcytosis of Caveolae-Targeted and Non-Targeted Cargo 
 Transport experiments indicate that myr-SIRK stimulation can increase the transport of 
receptor-bound native caveolar cargo (albumin) as well as nonspecific fluid phase transport of 70 
kDa dextran (diameter ~5 nm) (Figure AI.3c,d). This increase in transport is seen as early as 20 
minutes after stimulation and continues for 24 hours. As a control, FITC-inulin with a molecular 
weight of 2 to 5 kDa primarily passes through monolayers by paracellular diffusion, and its 
transport is not altered by myr-SIRK, providing further evidence that myr-SIRK does not affect 
paracellular diffusion (Figure AI.3e). Although there is minimal evidence for a change in tight 
junction integrity and consequently paracellular transport, the analysis of active transcytosis can  
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Figure AI.4 myr-SIRK Stimulates Antibody Transcytosis 
myr-SIRK stimulates dextran (a), albumin (b), and antibody transport (d), but not inulin (c) transport. 
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be isolated by observing the transport of pre-bound albumin. In these assays, it is clear that myr-
SIRK can increase the rate of albumin transcytosis by HUVEC cells (Figure AI.3b). 
AI.4.4 Stimulation of Antibody Transcytosis 
 Antibody transcytosis in the presence of myr-SIRK was quantified to determine if 
increased caveolar-based transcytosis could improve the transport of therapeutic agents. These 
data show that antibody transport is increased, along with both 70 kDa dextran and albumin 
(Figure AI.4a,b). Unfortunately, these data also reveal that HUVEC transcytosis is variable, 
depending on the batch of HUVECs used for the assays. Although the resistance measurements 
were the same between batches, baseline transport of inulin, albumin, and dextran are all 
increased by an order of magnitude with a new batch of HUVECs purchased from Lifeline 
Technologies (Figure AI.4). Unfortunately, it is unclear whether increased inulin transport in this 
second batch is due to increased paracellular diffusion or increased transcytosis at baseline. 
Despite the increased baseline transport, myr-SIRK stimulation is still able to induce an increase 
in antibody transport (Figure AI.4d), providing further support that stimulated caveolar transport 
can improve delivery of therapeutic macromolecules or nanoparticles to extravascular sites. 
 
AI.5 Discussion 
 Transvascular transport is controlled by the endothelium and can be separated into 
transcellular or paracellular transport. Paracellular transport relies on diffusion past endothelial 
tight junctions and is limited to particles smaller than 2 nm. Transcellular transport is often 
attributed to caveolar transcytosis and can transport particles of up to 100 nm.5 Schnitzer et al. 
have demonstrated the importance of caveolar transcytosis by endothelial cells in the 
transvascular delivery of albumin and albumin-bound molecules.10, 11 This constitutive process 
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can be leveraged for the transport of nanoparticles by targeting nanoparticles to endothelial 
caveolae via surface modification with antibodies to caveolar surface markers. For instance, 
conjugation of aminopeptidase P (a marker of caveolae on the endothelium of lung tissue) 
antibodies to the surface of nanoparticles allows nanoparticles to be quickly transcytosed and 
delivered into the extravascular space in the lungs.8 Unfortunately, it appears as though the speed 
of this process is dependent on the tissue, as lung transcytosis occurs an order of magnitude 
quicker than transcytosis in the tumor. Moreover, this transport paradigm requires the 
challenging process of identifying endothelial surface markers which are localized to caveolar 
structures.25 
 As an alternative, stimulation of caveolar transcytosis in an organ-specific manner may 
serve as an additional route to improve transvascular transport. By increasing the rate of 
transcellular transport, nanoparticles can be actively taken up by both active targeting as well as 
fluid phase transport and delivered to the interstitial space. Similar methods have been published 
by Ruoslahti et al. by increasing paracellular transport in tumors.26 To this end, our data suggest 
that, in in vitro tissue culture assays, stimulation of caveolar transcytosis by myr-SIRK can 
improve the transport of both caveolar targeted (albumin) and non-targeted (dextran) transport 
without altering endothelial integrity. Importantly, transport of natural “nanoparticles” such as 
IgG antibodies with a maximum dimension of ~15 to 20 nm can be increased as well. 
 Unfortunately, our data also highlight the difficulties of working with primary endothelial 
cells, including heterogeneity in basal transport rates and irregularities in cell behavior in a non-
native setting. Moreover, HUVEC monolayers do not recapitulate vascular endothelium due to a 
lack of shear stress in the lumen and supporting pericytes on the basal surface. Under these in 
vitro conditions, HUVECs are known to produce leaky monolayers, which may contribute to a 
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high baseline transport of control molecules in the un-stimulated condition.27-29 Additionally, 
shear stress is known to transiently induce caveolin-1 phosphorylation in cultured HUVECS, 
suggesting that media exchange can activate HUVEC monolayers, further increasing the baseline 
transport measured at the early 20-minute time point.30 
 Based on these findings, our observation of increased transport in myr-SIRK-treated 
monolayers suggests that despite the high basal transport in vitro, myr-SIRK stimulation is able 
to yield a quantifiable increase in transport. Therefore, it is likely that the effects of myr-SIRK 
will be greater in vivo where paracellular transport is lower and basal transcytotic rates are not 
transiently augmented by media exchange. Moreover, cultured HUVECs are known to harbor 
fewer caveolae than native endothelium. An increased number of caveolae in vivo may indicate 
that maximum transport by native endothelium will be higher than that of HUVEC monolayers.31 
Taken together, we expect stimulation of transcytosis to provide additional benefits in 
nanoparticle extravasation in vivo over baseline passive diffusion or caveolae targeted transport. 
 Before these studies can be accomplished, targeting mechanisms to deliver myr-SIRK in 
vivo must be developed. In unpublished work from our lab, Sinha et al. demonstrate that lipid-
conjugated peptides can be delivered into the cytoplasm of cells to alter PAR-1 signaling using 
perfluorocarbon (PFC) nanoemulsions. This finding implies that PFC nanoparticles are a viable 
platform for the targeted delivery of myr-SIRK to endothelium based on their cell surface 
markers.32 Combined with PFC delivery strategies, the use of dorsal skin windows or intra-vital 
2-photon microscopy can allow the quantitative measurement of myr-SIRK stimulated 
transcytosis in vivo.9  
 The need for new mechanisms to drive extravasation of nanoparticles is greatest in 
tissues with low paracellular transport and slower rates of transcytosis, notably tumors and 
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cardiac tissue. By stimulating transcytosis in an organ-specific manner, nanoparticle 
biodistribution can be improved without the induction of vascular leakiness. Such strategies can 
be used to increase the transport of caveolae-targeted cargos as well as the fluid phase transport 
of non-targeted cargos. Although a robust delivery mechanism for myr-SIRK remains to be 
tested, stimulated transcytosis remains a potential mechanism by which nanoparticle therapy can 
be improved. 
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